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ALT: alanine aminotransaminase 
AST: aspartate aminotransaminase 
AT: adipose tissue 
BMI: body mass index 
CK18: caspase-cleaved cytokeratin-18 
CRP: c-reactive protein 
CT: computed tomography 
CVD: cardiovascular disease 
DNL: de novo lipogenesis 
FA: fatty acid 
FABP4: fatty acid binding protein 4 
FAS: fatty acid synthase 
FATP: fatty acid transporter protein 
FFA: free fatty acids 
FxR: farnesoid X receptor 
GGT: γ-glutamyl transferase 
GLP-1: glucagon-like peptide-1 
GNG: gluconeogenesis 
GWAS: genome-wide association studies 
HbA1c: glycosylated hemoglobin 
HDL-C: high density lipoprotein cholesterol 
HGP: hepatic glucose production 
HOMA2-IR: homeostatic model assessment method insulin resistance 
IL-1β: interleukin 1β 
IL-6: interleukin 6 
IL-7: interleukin 7 
LDL-C: low density lipoprotein cholesterol 
LPL: lipoprotein lipase 
LPS: lipopolysacharide 
LXRα: liver X receptor alpha 
MetS: metabolic syndrome 
MR: nuclear magnetic resonance 
MUFA: monounsaturated fatty acids 
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NAFLD: non-alcoholic fatty liver disease 
NAS: NAFLD activity score 
NASH: non-alcoholic steatohepatitis 
NEFA: nonsterified fatty acid 
NFS: NAFLD fibrosis score 
NL: normal liver 
PPARα: peroxisome-proliferator-activated receptor α 
PPARγ: peroxisome-proliferator-activated receptor γ 
PPARδ: peroxisome-proliferator-activated receptor δ 
PTX: pentoxyphylline 
PUFAs: polyunsaturated fatty acids 
QM: chylomicrons 
RAS: renin–angiotensin system 
ROS: reactive oxygen species 
SAT: subcutaneous adipose tissue 
SFA: saturated fatty acids 
SNP: single nucleotide polymorphism 
SREBP1c: sterol-regulatory-element-binding protein 
SS: Simple steatosis 
T2DM: type 2 diabetes mellitus 
TCA: tricarboxylic acid cycle 
TG: triglycerides 
TGFβ1: transforming growth factor beta-1 
TNFRI: tumour necrosis factor receptor I 
TNFRII: tumour necrosis factor receptor II 
TNFα: tumour necrosis factor alpha 
TZD: thiazolidinedione 
VAT: visceral adipose tissue. 
VLDL: very low density lipoprotein 
WAT: white adipose tissue 
WC: waist circumference 
WHR: waist-hip ratio 
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1. Obesity as a 21st century epidemic and 
its global impact 
Obesity is defined as a condition characterized by an excess of 
body fat mass and therefore of adipose tissue. Under normal 
conditions of living, obesity results from an imbalance between 
energy intake and the energy expenditure through physical 
activity 1.   
The worldwide prevalence of obesity is increasing at an 
alarming rate in adults, adolescents and children, with adverse 
consequences for human health. The World Health 
Organization defines obesity as the epidemic of the 21st 
century. This "obesity epidemic" also parallels the rapid and 
substantive increase in our understanding of the molecular 
pathways and physiological systems underlying the regulation 
of energy balance.   
Obesity is a chronic and multifactorial condition that results 
from the interaction between genotype and environment, with 
consequent increased systemic inflammation. To characterize 
obesity, body mass index (BMI) is used given its 
reproducibility, ease of use and ability to reflect adiposity in 
most of the population. BMI, which estimates excess weight 
relative to a certain height, is the ratio between the weight in kg 
and height in meters squared. Considering that obesity is 
established using BMI > 30 kg/m2 as a cutoff point, the 
following classification is applied: 25.0–26.9 for grade I 
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overweight, 27.0–29.9 for grade II overweight (preobesity), 
30.0–34.9 for grade I obesity, 35.0–39.9 for grade II obesity, 
40.0–49.9 for grade III or morbid obesity (MO) and ≥ 50 for 
grade IV or extreme obesity 2. 
The prevalence of obesity in the Spanish adult population aged 
between 25 and 64 years is estimated as 15.5%, with a higher 
prevalence in women (17.5%) than in men (13.2%) and a 
higher proportion of obese people in the Northwest region, 
Murcia, southern Spain and the Canary Islands. Grade II 
obesity affects 0.79% of men and 3.1% of women aged 
between 25 and 60 years, whereas 0.3% of males and 0.9% of 
women are morbidly obese. Data from the latest WHO survey 
show an absolute increase of 6% in obesity rates over the past 
14 years 2. For the population aged over 65 years, the 
estimated prevalence of obesity is 35%, with a prevalence of 
30.9% among men and 39.8% among women 3. 
According to current WHO data for 2014 the prevalence of 
overweight in the population over 18 years was 66.2 (59.3 to 
72.2) % and the prevalence of obesity in the population over 
18 years was 22, 8 (16.7 to 29.3) % 4 (Figure 1). 
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Figure 1. Epidemiology of Obesity. Data WHO report in February 
2015. 
Obesity is a known and independent risk factor for developing 
diabetes mellitus, insulin resistance (IR), dyslipidemia, high 
blood pressure, gallstones, sleep apnea syndrome, 
osteoarthritis, different neoplasms and thrombosis 5. In fact, 
obese individuals are estimated to have increased mortality 
compared to normal-weight individuals. Despite considerable 
progress in diagnosis, prevention and treatment, 
cardiovascular disease remains the leading cause of death 
worldwide 6.     
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Metabolic syndrome (MetS), a determining factor for 
cardiovascular disease and type 2 diabetes (T2DM), is defined 
as a group of metabolic disorders including abdominal obesity 
7, atherogenic dyslipidemia (hypertriglyceridemia and/or low 
high-density lipoprotein cholesterol (HDL-C)), high blood 
pressure and impaired glucose metabolism 8,9.  
Increased visceral fat content is also associated with type 2 
diabetes, insulin resistance and coronary heart disease 10. 
Even within the normal BMI range, the accumulation of visceral 
fat remains an independent cardiovascular risk factor. This 
observation led researchers and physicians alike to consider 
that the clinical diagnosis of visceral obesity may be more 
important than the actual diagnosis of obesity by body mass 
index 7. 
Central obesity and insulin resistance are considered the 
cornerstones in the pathogenesis of the metabolic syndrome. 
Insulin resistance is associated with other disorders that entail 
an additional increase in cardiovascular risk along with other 
abnormalities associated with lipid factors, changes associated 
with prothrombotic factors and proinflammatory factors 11. 
In clinical practice, abdominal waist circumference and waist-
hip ratio (WHR) are the anthropometric measurements 
commonly used to diagnose abdominal obesity.  These 
measures are correlated with the total amount of visceral fat 
measured by abdominal CT scan 12. 
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For this reason, the Adult Treatment Panel-III (ATP-III) of the 
National Cholesterol Education Program (US) approved the 
use of abdominal waist circumference as an important 
component of the clinical diagnostic criteria of metabolic 
syndrome, using a waist circumference ≥ 102 cm in men and ≥ 
88 cm in women as the cutoff points 7. Obesity is associated 
with low-grade chronic inflammation, characterized by an 
increase in plasma levels of proinflammatory cytokines from 
adipose tissue (AT) and immune cells present in the tissue, 
and is causally involved in the development of insulin 
resistance 13.    
Although numerous estimates have been made regarding the 
disease cost of obesity, its real impact on the health burden of 
a country was most vividly demonstrated by the UK 
government’s Foresight Report, which showed that the medical 
costs of the chronic diseases induced or amplified by weight 
gain were so great that should obesity rates continue to 
increase, this problem would become a crippling burden on the 
health system and indeed would be unsustainable. Whereas 
many estimates of the economic impact of obesity in different 
societies exist, these often relate only to direct medical costs 
and do not include the far greater impact on the individuals’ 
capacity to work and the burden placed on relatives later in life 
because of the additional physical and other handicaps 
involved. These indirect costs may amount to nearly 4% of a 
nation’s gross domestic product 14. 
UNIVERSITAT ROVIRA I VIRGILI 
NEW ADIPOKINES VASPIN AND OMENTIN, CIRCULATING LEVELS, GENE EXPRESSION IN ADIPOSE TISSUE AND RELATIONSHIP OF CIRCULATING LEVELS  WITH NONALCOHOLIC FATTY LIVER DISEASE 
David Gerardo Riesco Acevedo 
II. INTRODUCTION 
 
28 
 
 
2. Adipose tissue and its endocrine activity 
Until late last century, adipose tissue was characterized by the 
storage and release of lipids. However, with the recognition of 
obesity as a major public health problem and progress in the 
study of the neuroendocrine system as a regulator of energy 
homeostasis, adipose tissue became a priority, making it 
possible to identify its extraordinarily dynamic behavior and 
highly active role as an endocrine organ 15,16,17.  
Adipose tissue represents approximately 20% of body weight 
in men and 20–30% in women, making it one of the largest 
organs in the body.  
In humans, fat formation occurs relatively early in the prenatal 
period between weeks 14 and 16. Throughout life, two 
particularly sensitive periods for changes in the cellularity of 
white adipose tissue (WAT) have been proposed, with a rapid 
expansion in adipose tissue mass occurring after birth and 
between 9–13 years 18. 
Two types of adipose tissue are recognized based on their 
cellular structure, location, color, vascularization and function: 
brown adipose tissue and white adipose tissue.  
Brown adipose tissue is present in a variety of mammals, 
being of special importance in those that hibernate. Its name 
originates from its brownish hue due to the high number of 
mitochondria and cytochromes.   
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In humans, brown adipose tissue is present only in newborns, 
and its function is to regulate thermogenesis. The thermogenic 
function of brown adipose tissue is due to its gene expression 
pattern that determines the presence of a protein called UCP-1 
(uncoupling protein-1) in its mitochondria, which acts on the 
respiratory chain by uncoupling electron transport chain ATP 
synthesis in cellular oxidation 19. 
 
White adipose tissue, to which we will be referencing from this 
point forward, actively participates in the regulation of various 
biological functions (Rasouli). WAT is distributed in the body in 
two main anatomical locations: the hypodermis regions for 
subcutaneous adipose tissue (SAT) and adipose tissue located 
around the organs for visceral adipose tissue (VAT) 20. 
  
 
In females, subcutaneous fat is most abundant in the gluteo-
femoral regions and the breast. In males, the main 
subcutaneous depots include the nape of the neck, the area 
over the deltoid and triceps muscles and the lumbosacral 
region, whereas excess fat is mainly stored in the visceral or 
intra-abdominal region, omentum, mesenteries and 
retroperitoneal area. This sexual dimorphism is responsible for 
the particular body shape of males and females, termed the 
android and gynecoid fat distribution. Furthermore, the fat 
distribution regional differences also result from variations in 
gene expression characteristics underpinning a diverse 
hormone receptor distribution, adipokine secretory profile and 
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expression pattern, as well as from specific local 
environmental features related to innervation and 
vascularization 21. Numerous studies have revealed that 
android obesity correlates more often with elevated mortality 
and the risk of developing type 2 diabetes mellitus (T2DM), 
dyslipidemia, hypertension and atherosclerosis than gynecoid 
obesity 21. 
Regarding lipid metabolism in adipose tissue, some of the 
hormones that modulate lipogenesis and lipolysis are 
catecholamines, insulin, glucagon, cortisol and ACTH. 
However, their actions are different depending on the type of 
adipose tissue involved 22.  
Visceral adipose tissue has a higher triglyceride (TG) 
clearance rate than subcutaneous fat and is capable of greater 
lipolysis compared to subcutaneous adipose tissue 22. 
Additionally, visceral adipose tissue has higher β-adrenergic-
receptor expression, is more sensitive to steroids and has 
higher expression of inflammatory cytokines 23.  
Adipocytes from visceral adipose tissue are larger, more 
resistant to insulin action and more metabolically active. Thus, 
visceral adiposity has greater influence on the appearance of 
comorbidities associated with obesity and it may be considered 
an indicator of adipose tissue metabolic dysfunction 24, 25.  
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Differences also exist between adipose tissues from the 
vascular standpoint. Unlike subcutaneous fat, visceral adipose 
tissue drains directly into the portal circulation 24.   
Macrophage infiltration of adipose tissue is known to occur 
during the development of obesity, whereas the rate of 
monocyte infiltration is recognized to be higher in visceral than 
in subcutaneous adipose tissue 26, 27. 
At the nervous system level, both visceral and subcutaneous 
adipose tissues are innervated by the autonomic nervous 
system and are under neuroendocrine control. Stimulation of 
the parasympathetic nervous system leads to an anabolic state 
with decreased lipolysis, whereas stimulation of the 
sympathetic nervous system produces a catabolic state with 
reduced adipogenesis and the stimulation of lipolysis 24. 
With regard to its composition, adipose tissue is notably 
composed of adipocytes embedded in a web of loose 
connective tissue containing precursors of adipocytes, 
fibroblasts, immune cells (mainly macrophages and 
lymphocytes) and various other cell types 17. 
Under maintained positive energy-balance circumstances, 
adipose mass expansion occurs initially through enlargement 
of the existing fat cells (hypertrophy). The persistence of these 
circumstances leads to severe obesity with an increase in the 
total fat cell number (hyperplasia). Prolongation of the positive 
energy balance over time leads to white adipose tissue 
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enlargement with hypertrophic growth predominating in adult-
onset obesity 18.  
 
Figure 2. Factors affecting the regulation of adipogenesis BMPs, 
bone morphogenetic proteins; EGF, epidermal growth factor; IGF-1, insulin-like 
growth factor-1; IGFBP-1/2, insulin-like growth factor-binding protein 1 and 2; IL, 
interleukin; LIF, leukemia-inhibitory factor; MCSF, macrophage colony-stimulating 
factor; PAI-1, plasminogen activator inhibitor-1; PDGF, platelet-derived growth 
factor; PGF, prostaglandin F; PPARs, peroxisome-activated receptors; TGF-β, 
transforming growth factor-β; TNF-α, tumor necrosis factor-α. 
 
The majority of the total lipid content stored in fat cells is 
represented by triacylglycerols (constituted mainly by oleic and 
palmitic acids) and to a smaller degree by diacylglycerols, 
phospholipids, unesterified fatty acids and cholesterol, which 
are continuously being mobilized and renewed. Mature white 
fat cells are mainly unilocular, containing only a single large 
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lipid droplet. In contrast, developing white adipocytes are 
transiently multilocular, exhibiting multiple smaller lipid droplets 
before these finally coalesce into a single large drop 28. A 
narrow rim around the lipid droplet contains the cytoplasm with 
a thin basal lamina surrounding the cell. The cytoplasm 
contains few mitochondria with loosely arranged membranous 
cristae around the nucleus, exhibits a small Golgi zone and is 
filled with free ribosomes, containing only a limited number of 
short profiles of the granular endoplasmic reticulum (ER) with 
occasional lysosomes 28.    
The adipocyte and its secretory products have been implicated 
in a wide variety of physiological processes. Adipose tissue 
produces and secretes hormone-like signaling molecules, 
cytokines and adipokines impacting multiple target organs 29. 
Moreover, it expresses a wide range of receptors, which 
causes it to respond to numerous metabolic and endocrine 
stimuli involved in modulating blood pressure, glucose 
metabolism, inflammation and atherosclerosis 17, 29 (Figure 2). 
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Figure 3. Main factors produced by adipose tissue, a 
multifunctional endocrine organ. ANP, atrial natriuretic peptide; ASP, 
acylation-stimulating protein; BMP, bone morphogenetic proteins; HGF, hepatocyte 
growth factor; IGF-1, insulin growth factor-1; IGF-BPs, insulin-like growth factor-
binding proteins; IL, interleukin; LPL, lipoprotein lipase; PAI-1, plasminogen activator 
inhibitor-1; PDGF, platelet-derived growth factor; PGE2, prostaglandin E2; PGF2α, 
prostaglandin F2α; sTNFRs, soluble receptors of tumor necrosis factor-alpha; TNF-α, 
tumor necrosis factor-α; VEGF, vascular endothelial growth factor.  
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3. Adipocytokines in visceral adipose 
tissue, subcutaneous adipose tissue and 
their involvement in inflammation 
Adipose tissue is a highly active organ that is now recognized 
to be an active participant in energy homoeostasis and 
physiological functions such as immunity and inflammation 30. 
Adipose tissue is known to express and secrete a variety of 
products known as “adipokines”, including leptin, adiponectin, 
resistin and visfatin, as well as cytokines and chemokines such 
as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and 
monocyte chemoattractant protein-1 (MCP-1) (Figure 3 and 
4). The release of adipokines by either adipocytes or adipose 
tissue-infiltrated macrophages leads to a chronic 
subinflammatory state that could play a central role in the 
development of insulin resistance and type 2 diabetes and may 
increase the risk of obesity-associated cardiovascular disease 
30.  
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Figure 4. Secretion of inflammatory adipokines from adipose tissue 
in obese state. Secretion of inflammatory adipokines from adipose tissue in the 
obese state. In the obese state, the enlarged adipose tissue stores trigger the 
dysregulated secretion of adipokines and the increased release of free fatty acids. The 
free fatty acids and proinflammatory adipokines circulate to metabolic. tissues, including 
skeletal muscle and liver, and modify inflammatory responses as well as glucose and lipid 
metabolism, thereby contributing to metabolic syndrome. Additionally, obesity induces a 
phenotypic switch in adipose tissue from anti-inflammatory (M2) to proinflammatory (M1) 
macrophages. In contrast, the adipose production of insulin-sensitizing adipokines with 
anti-inflammatory properties, such as adiponectin, is decreased in the obese state. The 
red arrows indicate increased (pointing upward) or decreased (pointing downward) 
responses with obesity. ANGPTL, angiopoietin-like protein; ASP, acylation-stimulating 
protein; IL, interleukin; MCP-1, monocyte chemotactic protein; NAFLD, nonalcoholic fatty 
liver disease; PAI-1, plasminogen activator inhibitor-1; RBP-4, retinol-binding protein-4; 
SAA, serum amyloid A; SFRP5, secreted frizzled-related protein 5; TGF-β, transforming 
growth factor-β; TNF-α, tumor necrosis factor-α. Adapted from Un Ju Jung et all. Int J Mol 
Sci. 2014 Apr; 15(4): 6184–6223.  
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3.1 Proinflammatory molecules  
3.1.1 Leptin 
Leptin, a peptide hormone produced and secreted by adipose 
tissue in proportion to its mass, acts both centrally on the 
hypothalamus and peripherally to regulate several metabolic 
and inflammation-related functions. As the product of the 
obese gene (ob), leptin is a cytokine-like 16-kDa peptide 
whose effects are mediated through the long form of its 
receptor Ob-Rb 31, 32.   
Leptin is produced proportionally to the body fat mass and 
controls appetite and energy expenditure through 
hypothalamic pathways 32, 33. Most obese patients have high 
leptin levels, and the majority of obese subjects are leptin 
resistant, which establishes that obesity is the result of 
hormone resistance 34. The mechanisms involved in leptin 
resistance are complex and likely involve both impaired leptin 
transport across the blood-brain barrier into the central 
nervous system (CNS) and induction of the suppressor of 
cytokine signaling-3 (SOCS3), resulting in decreased leptin 
signaling via the Janus kinase-signal transducer and activator 
of transcription (JAK-STAT) and phosphoinositol-3 (PI-3) 
kinase signaling pathways 35. High-fat and more recently, high-
fructose diets 36, 37, have been implicated in the induction of 
central leptin resistance via increased SOCS3 and/or 
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decreased signal transducer and activator of transcription 
(STAT) phosphorylation 38.  
This hormone-like adipokine modulates body weight, food 
intake, fat stores, pancreatic islets cells, growth hormone 
levels, immunologic homeostasis, hematopoiesis, 
angiogenesis, wound healing, osteogenesis and 
gastrointestinal function 39, 40. 
Leptin levels are proportional to insulin levels and inversely 
proportional to glucocorticoid concentrations 39, 41, 42. Food 
deprivation decreases leptinemia, inhibits the immune 
response and causes lymphoid tissues to atrophy 43, 44.  
Moreover, leptin induces the secretion of the proinflammatory 
cytokines interferon-gamma (IFN-γ) and interleukin-2 (IL-2) in 
stimulated T-cells from human peripheral or umbilical cord 
blood 31, 43. Human monocytes are activated by leptin as 
shown by the expression of surface markers 45. In addition to 
decreasing leptin levels, weight loss results in a lower 
leukocyte count and lower plasma levels of TNF-α, C-reactive 
protein (CRP) and Von Willebrand factor 31. 
More recently, a role has been proposed for inflammation 
within the hypothalamus regarding the impairments of insulin 
and leptin signaling and perturbations of energy and glucose 
homeostasis 46. Leptin has also been reported to bind to C-
reactive protein and this binding may contribute to leptin 
resistance. Moreover, leptin may potentially promote a 
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proinflammatory state by increasing hepatic CRP expression 
47.  
 
3.1.2 Chemerin 
Chemerin, a chemokine highly expressed in liver and white 
adipose tissue, was initially described as a protein with a 
complex immune system function 48, 49. This protein has 
recently been identified as a new adipokine that regulates the 
development and metabolic function of adipocytes as well as 
glucose metabolism in the liver and skeletal muscle. Several 
research lines indicate that chemerin levels in plasma are 
elevated in obese patients and moreover and that these levels 
are correlated with various components of the metabolic 
syndrome. Thus, this double role of chemerin in inflammation 
and metabolism may provide a link between chronic 
inflammation and obesity, along with other obesity-associated 
diseases such as type 2 diabetes and cardiovascular disease 
48. 
Chemerin exerts its metabolic and immunomodulatory effects 
by binding to its receptor ChemR23 (CMKLR1). Two other G-
protein-coupled receptors (GPRs) have been reported to bind 
chemerin with high affinity, namely, GPR1 50 and C-C 
chemokine receptor-like 2 (CCLR2) 51. GPR1 is most closely 
related to ChemR23; however, the expression pattern of GPR1 
is different from ChemR23, with the main expression of GPR1 
occurring in the liver, intestine, kidney and adipose tissue. 
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CCLR2 is expressed at high levels by lung endothelial cells 
and at lower levels by liver endothelium in vivo 52. 
 
Furthermore, chemerin is crucial for normal adipocyte 
differentiation and modulates the expression of adipocyte 
genes involved in glucose and lipid homeostasis, such as 
glucose transporter-4, fatty acid synthase and adiponectin via 
its own receptor 53. 
 
In obesity, chemerin expression and its circulating 
concentration are positively related to metabolic syndrome 
indices such as increased blood pressure and triglyceride 
levels. Weight loss induced by caloric restriction or bariatric 
surgery is associated with chemerin reduction 54, 55. 
In a recent study, it was suggested that fasting levels of 
chemerin might be used as a biomarker to identify insulin 
resistance in healthy men without typical characteristics of 
metabolic disorders 56. 
Studies demonstrate that chemerin regulates adipogenesis, 
causes insulin resistance, increases the risk for metabolic 
syndrome and modulates the immune system by enhancing 
the chemotaxis of dendritic cells and macrophages 57, 58. 
Further studies are needed to determine the physiological role 
of chemerin in glucose metabolism and to identify chemerin’s 
target tissues as well as relevant signal transduction pathways. 
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3.1.3 Resistin 
Resistin is a small cysteine-rich protein secreted as a 94-
amino-acid polypeptide that was first identified by Steppan 
during a study of the effects of peroxisome proliferator-
activated receptor gamma (PPAR-γ) agonists on glucose 
homeostasis. Steppan named this protein ‘resistin’ for its 
property of ‘resistance to insulin’ in mice and this gene was 
later designated as Retn 59.  
Expression of resistin mRNA is markedly increased by the 
proinflammatory cytokines interleukin-1 (IL-1), IL-6 and TNF-α, 
and by lipopolysaccharides (LPS) 60. Moreover, resistin levels 
are mutually correlated with those of cell-adhesion molecules 
such as intercellular adhesion molecule-1 (ICAM-1) in patients 
with obstructive sleep apnea and in atherosclerotic patients are 
positively associated with other markers of inflammation, such 
as soluble tumor necrosis factor receptor (TNFR) type II and 
lipoprotein-associated phospholipase A2 61, 62. Similarly, 
stimulation of human macrophages with LPS led to increased 
resistin mRNA expression via a cascade involving the 
secretion of proinflammatory cytokines, whereas LPS 
administration to human volunteers is associated with 
dramatically increased circulating resistin levels, thus 
suggesting that this molecule may act as a critical mediator of 
the insulin resistance associated with sepsis and possibly 
other inflammatory conditions. In further support of its 
proinflammatory profile, resistin also up-regulates the 
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expression of vascular cell-adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 and CCL2 by human 
endothelial cells and induces these cells to release endothelin-
1 63. 
Human resistin, however, is mainly secreted by peripheral 
blood mononuclear cells 64. It competes with LPS for the 
binding to Toll-like receptor 4 and is thus involved in the 
inflammatory process. The expression of human resistin is 
predominantly localized in the macrophages and stromal cells 
in adipose tissue rather than the adipocytes 65, 66. A high level 
of resistin gene expression was observed in human 
preadipocytes, which decreased during adipocyte 
differentiation. Notably, the relationship between resistin and 
insulin resistance in humans is complicated; it remains a 
subject of debate because some studies revealed a positive 
correlation between resistin and insulin resistance 67, whereas 
others failed to detect changes in resistin levels in obesity, 
insulin resistance or T2DM 68, 69.  
As a secreted circulating protein, resistin may exert its 
functions in both endocrine and paracrine manners 66. To date, 
resistin is widely accepted to play a pivotal role in several 
inflammatory conditions and in malignancies 70, 71. 
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3.1.4 Visfatin 
Visfatin, discovered by Fukuhara et al and originally isolated as 
a presumptive cytokine named pre-B-cell colony-enhancing 
factor (PBEF) that enhances the maturation of B-cell 
precursors 72, is an adipokine mainly produced by visceral 
WAT. Visfatin was originally described as having a potential 
glucose-lowering effect because of its nicotinamide 
phosphoribosyltransferase (Nampt) activity 72.  
 
Revollo et al demonstrated that the extracellular form of Nampt 
(eNampt/visfatin/PBEF), which is secreted through a non-
classical secretory pathway, did not show insulin-mimetic 
effects in vitro or in vivo but rather exhibited robust 
nicotinamide adenine dinucleotide (NAD) biosynthetic activity. 
Haplodeficiency and chemical inhibition of Nampt resulted in 
significantly decreased NAD biosynthesis and glucose-
stimulated insulin secretion in pancreatic islets in vitro and in 
vivo. Conversely, the administration of the Nampt reaction 
product nicotinamide mononucleotide (NMN) resulted in an 
amelioration of these defects. In summary, the current data 
suggest that adipose tissue as a natural source of 
eNampt/visfatin/PBEF may regulate β-cell function through the 
secretion of eNampt and extracellular biosynthesis of NMN 73. 
Later studies showed that plasma visfatin was correlated with 
various metabolic states including obesity, increased visceral 
fat mass and diabetes in humans 74.  
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Visfatin also appears to mediate inflammatory responses in 
monocytes by the induction of the proinflammatory cytokines 
interleukin-IB (IL-1B), IL-6 and TNF-α. However, higher 
concentrations of visfatin increase the expression of anti-
inflammatory cytokines, for example, interleukin-10 (IL-10). An 
important implication of this new adipokine in the inflammatory 
mechanisms of obesity beginning during childhood has been 
proposed 75. 
 
A recent meta-analysis showed that plasma visfatin was 
increased in subjects with obesity, type 2 diabetes mellitus, 
metabolic syndrome and cardiovascular diseases 76. 
Circulating visfatin was positively associated with insulin 
resistance, a finding that implied visfatin stimulation in 
hyperglycemia. Moreover, visfatin may have a direct role in 
vascular dysfunction and inflammation through iNOS up-
regulation 77. 
 
3.1.5 Retinol-binding protein-4 (RBP-4) 
Retinol-binding protein-4 is a recently identified adipokine. It 
belongs to the lipocalin (LCN) family of proteins that transport 
small hydrophobic molecules. RBP-4 is a transport protein for 
retinol (vitamin A) in the circulation, which it transports from the 
liver to the peripheral tissues. Serum RBP-4 levels are 
increased and positively correlated with BMI in obese non-
diabetic and diabetic subjects 78. 
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Although RBP-4 is primarily secreted by the liver, visceral WAT 
is also an important source of this adipokine 79. In experimental 
models, Yang et al showed that serum RBP-4 contributed to 
insulin resistance via the induced expression of gluconeogenic 
enzymes in the liver and impaired insulin signaling in muscle 
80. The same authors reported that RBP-4 was increased in 
human obesity and type 2 diabetes. In the latter, a positive 
relationship was found with RBP-4 and insulin-resistance 
severity in obese, glucose-intolerant, type-2 diabetics and 
nonobese subjects with a strong family history of T2DM 81.  
 
To date, the majority of clinical studies in children and 
adolescents support the hypothesis that RBP-4 has a relevant 
role in obesity and the development of insulin resistance and 
T2DM 82. It appears to be involved in the early phases of the 
development of insulin resistance and other components of the 
metabolic syndrome, and as such, RBP-4 could be used as an 
additional marker for the early detection of subjects 
predisposed to developing T2DM, enabling early and vigorous 
intervention 82. Therefore, longitudinal studies investigating the 
prognostic value of RBP-4 are particularly needed in children 
and adolescents predisposed to developing these conditions. 
 
3.1.6 Interleukin-6 
Interleukin-6 (IL-6) is a proinflammatory factor produced by 
monocytes, fibroblasts and the stromal vascular fraction of 
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visceral WAT 83.  Visceral more than subcutaneous adipose 
tissue has a greater ability to secrete IL-6. However, adipose 
tissue is composed of numerous cells other than adipocytes, 
and most of the IL-6 is derived from the stromal vascular 
fraction, composed of endothelial cells and 
monocytes/macrophages 84. In the absence of inflammation, 
adipose tissue appears to contribute to 15–30% of circulating 
IL-6 85. 
  
IL-6 is a multifunctional cytokine that targets several tissues 
and cell types. One of its major actions is control of the hepatic 
production of inflammatory proteins such as C-reactive protein. 
A positive relationship exists between IL-6 levels in adipose 
tissue and circulating CRP levels, which is an important 
cardiovascular risk factor 86. Visceral adipose tissue produces 
three times more IL-6 than subcutaneous adipose tissue. This 
may explain, in part, the deleterious role of central obesity in 
cardiovascular diseases. Indeed, IL-6 visceral adipose tissue 
production could have a direct effect on hepatic metabolism as 
its venous drainage goes directly to the liver through the portal 
vein. Thus, IL-6 produced by intra-abdominal adipose tissue 
could directly contribute to visceral obesity-related 
hypertriglyceridemia by stimulating the hepatic secretion of 
triglycerides and very low density lipoprotein (VLDL) 87. 
Chronic elevation of IL-6 plasma levels and the increased 
cardiovascular risk related to an inflammatory state could be 
causes of insulin resistance. The proposed mechanism of this 
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biological effect is the reduction of glucose transporter-4 and 
insulin receptor substrate-1 expression in response to IL-6 
exposure 88. IL-6 also plays an anti-inflammatory indirect and 
dual role by reducing TNF-α and interferon-gamma stimulating 
interleukin-1 receptor antagonist (IL-1RA) 32.  
It is also possible that the chronic elevation of IL-6 circulating 
levels, more so than acute IL-6 secretion, has a weak or no 
effect on muscle in vivo, whereas it could contribute to whole-
body insulin resistance, particularly in liver and adipose tissue 
89. 
 
3.1.7 Tumor necrosis factor-alpha  
Tumor necrosis factor-alpha (TNF-α) was originally described 
to induce the necrosis of tumors after acute bacterial infection. 
However, this cytokine is also involved in inflammation, 
autoimmune diseases, tumorigenesis, metastasis, viral 
replication, septic shock and fever. A large variety of agents 
may induce its production, such as endotoxin, viruses, 
cytokines (e.g., IL-1) and drugs. TNF-α is suppressed by 
interferon-α (IFN-α), IFN-b, IL-6 and by the 
immunosuppressive cytokines interleukin-4 (IL-4) and IL-10. 
Many drugs may inhibit the production of TNF-α, such as 
dexamethasone and cyclosporin A. TNF-α is produced by 
many cell types, ranging from the cells of the immune system 
(monocytes, T lymphocytes, B lymphocytes, 
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polymorphonuclear cells) to tumor cells, fibroblasts and 
smooth muscle cells 90.  
 
TNF-α is a proinflammatory cytokine produced by numerous 
cells, but mainly macrophages and lymphocytes. In adipose 
tissue, TNF-α is primarily produced by resident macrophages. 
Adipocytes also produce TNF-α in rodents, whereas in 
humans, such production occurs at low levels. In rodents, 
TNF-α is involved in the pathophysiology of insulin resistance. 
One of the possible mechanisms by which this cytokine 
interferes with insulin sensitivity is through the abnormal 
phosphorylation of insulin receptor substrate (IRS)-1. However, 
as previously mentioned, TNF-α is poorly expressed in human 
adipose tissue, with no differences in fat depots. Moreover, its 
expression is slightly modified in human obesity, and the 
absence of its production in subcutaneous adipose tissue in 
obese and lean men has been demonstrated by direct 
arteriovenous balance measures 91. This finding indicates that 
adipose tissue is poorly or indirectly involved in the increased 
circulating concentrations of TNF-α observed in obesity. 
Nevertheless, it warrants consideration that TNF-α in 
experiments may accelerate atherosclerosis, mainly through 
the induction of adhesion molecule expression, VCAM-1, 
ICAM-1, MCP-1 and E-selectin in endothelial and vascular 
smooth muscle cells, resulting in altered endothelium-
dependent vasodilatation, and the promotion of endothelial cell 
apoptosis 92. 
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3.1.8 Lipocalin-2 
Lipocalin-2 (LCN-2), also known as neutrophil gelatinase-
associated lipocalin (NGAL), siderocalin, or 24p3, is a 25-kDa 
glycoprotein that binds and transports small hydrophobic 
molecules, such as retinoic acid, hormones and fatty acids. It 
is produced by immune cells, mainly neutrophils and 
adipocytes 93.  
In obese human subjects and animals, the circulating 
concentration of lipocalin-2 is augmented and positively 
correlated with body-fat mass, arterial blood pressure (ABP), 
the insulin resistance index, and abnormal lipid profiles 94.  
In mice, deficiency of this adipokine protects against the 
development of endothelial and cardiometabolic dysfunctions 
associated with genetic or dietary obesity. Moreover, when fed 
a high-fat diet (HFD), the administration of recombinant 
lipocalin-2 protein promotes endothelial dysfunction and 
induces adipose tissue inflammation 95, 96. 
An augmented lipocalin-2 level is likely to play a causative role 
in obesity-related cardiovascular complications, including 
hypertension and heart disease 94. 
LCN2 was initially shown to possess antibacterial properties, 
suppressing bacterial growth by binding and sequestering 
bacterial siderophores 97, 98. 
It is not known whether lipocalin-2-evoked endothelial 
dysfunction is related to non-esterified free fatty acids (NEFA)-
mediated lipotoxicity under obese conditions. NEFAs up-
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regulate and activate lipocalin-2 by promoting deamidation. 
The deamidated lipocalin-2 accumulates in arteries, inducing 
endothelial dysfunction and causing elevated arterial blood 
pressure 99. 
 
3.2 Anti-inflammatory molecules  
 
3.2.1 Adiponectin 
Adiponectin was discovered almost simultaneously by four 
groups and designated as adipocyte complement-related 
protein of 30 kDa (Acrp30). It is produced exclusively by the 
adipocyte fraction of adipose tissue 85. Whereas it is adipocyte 
protein that links visceral adiposity with insulin resistance and 
atherosclerosis, adiponectin is unique among adipocyte-
derived hormones in that its circulating concentrations are 
lower in obese that in normal-weight humans and animals 100. 
Adiponectin circulates as multimers, trimers, hexamers and 
higher molecular weight multimeric oligomers 100, 101; it has 
both an adaptor protein, APPL1, as well as two receptors, 
Adipo-R1 and Adipo-R2 that are the main adiponectin 
receptors with respect to glucose and lipid metabolism 102.  
Adiponectin mRNA expression varies according to the tissue, 
being lower in visceral than in subcutaneous tissue 103. 
The high-molecular-weight forms of the hormone have been 
implicated as being the most biologically active in increasing 
hepatic insulin sensitivity 100. 
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Circulating adiponectin levels are negatively correlated with 
fasting insulin concentrations and positively correlated with 
insulin sensitivity 100, 104. Low circulating adiponectin 
concentrations are predictive of the development of insulin 
resistance, T2DM and cardiovascular disease in humans 105, 
106. In addition to its effects on insulin sensitivity, adiponectin 
exhibits a vascular-protective effect early in the atherogenesis 
process by interfering with the regulation of adhesion molecule 
expression on vascular endothelial cells 107 and the 
transformation of macrophages into foam cells 108, also by 
modulating smooth muscle cell proliferation 109. Adiponectin 
induces endothelial VCAM-1, ICAM-1, and pentraxin-3 
expression 32. The hormone is an antioxidant and increases 
endothelial nitrous oxide production, acting to protect the 
vasculature by reducing platelet aggregation and 
vasodilatation 108, 110.   
Adiponectin also has anti-inflammatory effects that inhibit the 
activation of macrophages and protects against the 
development of atherosclerosis in vascular endothelium 111. It 
appears that many adiponectin anti-inflammatory properties 
derive from the anti-TNF-α effects that could partially explain 
its protective role in atherosclerosis. In contrast, adiponectin 
expression in human adipocytes is reduced by TNF-α and IL-6 
112. 
Relevant to its insulin-sensitizing actions, adiponectin 
decreases glucose production by isolated hepatocytes by 
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decreasing the mRNA expression of two essential 
gluconeogenesis enzymes, phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase, and activates AMP 
kinase, resulting in increased fat oxidation in liver and skeletal 
muscle leading to decreased ectopic fat deposition in these 
insulin target tissues 113. 
In humans, plasma adiponectin concentrations are influenced 
by age and gender, and the inverse relationship between 
adiponectin and body adiposity is more closely related to 
visceral rather than subcutaneous fat distribution 114. 
Although adiponectin does not cross the blood brain barrier, it 
may have effects in the CNS via increasing cytokine 
expression in brain endothelial cells 115. 
 
 
3.2.2 Apelin 
Apelin is a peptide produced and secreted by adipocytes, the 
stromal vascular fraction and cardiovascular tissues. The gene 
encoding the apelin receptor (APJ) shares the greatest 
sequence identity with the angiotensin receptor. In humans, 
apelin appears to function as a paracrine hormone and its 
levels are significantly increased by insulin in obese patients 
116. In addition to its role as an adipokine, apelin is expressed 
in the central nervous system (with particularly high expression 
in the hypothalamus), heart, skeletal muscle and stomach 117. 
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Apelin and APJ expression are found in many tissues where 
they play roles in satiety, immune function and fluid balance 
118. A positive correlation exists between plasma apelin levels 
and BMI. Furthermore, apelin administration has been found to 
decrease body adiposity and the serum levels of insulin and 
triglycerides in obese mice fed a high-fat diet. These findings 
suggest the presence of resistance to apelin, in a manner 
similar to insulin and leptin 119, 120, 121.  
Apelin increases the serum adiponectin level and decreases 
that of leptin. It regulates insulin resistance by influencing 
serum adiponectin levels, energy expenditure and the 
expression of uncoupling proteins in brown adipose tissue in 
mice 122. 
Apelin expression also closely correlates with TNF-α in AT of 
lean and obese individuals, and in vitro studies of cultured 
explants of human AT show an up-regulation of apelin in 
response to TNF-α 123. 
In particular, the ability of apelin to decrease lipolysis and 
induce vasodilatation with the subsequent reduction in blood 
pressure may open new therapeutic avenues 124. 
 
3.2.3 Nesfatin 
Nesfatin-1 (NEFA/nucleobindin-2-encoded satiety and fat-
influencing protein-1) is an 82-amino-acid peptide encoded in 
the N-terminal region of its precursor, nucleobindin-2 (NUCB-
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2) 111, 125. NUCB-2 was predicted to be processed by 
prohormone convertases (PC) to form nesfatin-1 125. 
Administration of the full-length nesfatin-1 or its 30-amino-acid 
midsegment (M30), considered its bioactive core, reduces food 
intake and fat mass in rodents 126, 115. Naresh Ramesh et al 
and others have identified nesfatin-1-like immunoreactivity in 
the pancreatic islet beta cells of rats, mice 126 and humans 114 
and found an insulinotropic effect for this peptide in vitro and in 
vivo 114, 126. Nesfatin-1 increases glucose-stimulated insulin 
secretion from beta cells by direct action involving Ca2+ influx 
through L-type calcium channels 127.  
Nesfatin-1 is emerging as an evolutionarily conserved, NUCB-
2-derived multifunctional peptide affecting major organ 
systems in vertebrates 128. 
 
When originally discovered, nucleobindin-2 was named 
because of its very high sequence similarity with another 
secreted protein, nucleobindin-1 (NUCB-1). Both NUCB-1 and 
NUCB-2 are homologous multi-domain Ca2+ and DNA binding 
proteins encoded by two unlinked genes. Human NUCB-1 and 
NUCB-2 exhibit 62% amino acid sequence identity and are 
remarkably conserved within the nesfatin-1 region 129, 128. 
NUCB-1 has been found within the nucleus, endoplasmic 
reticulum and cytoplasm of cells in the stomach, intestine, 
adrenal glands, pituitary, ovary and testis 130. 
The endogenous expression profile of NUCB-1 was 
characterized recently by immunofluorescence staining, 
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showing NUCB-1 localization in the endocrine pancreas along 
with insulin, glucagon, somatostatin, ghrelin and pancreatic 
polypeptide immunopositive cells 130. 
Overall, nesfatin-1 is now emerging as a multifunctional 
peptide with reproductive, cardiac and endocrine functions 
131,132,128.  
Recently, nesfatin-1 was found to exert cardiovascular actions 
in the brain by increasing sympathetic nerve activity, thereby 
increasing mean arterial pressure 133. Furthermore, subjects 
with acute myocardial infarction had relatively lower serum 
nesfatin-1 concentrations than healthy volunteers 134. This 
finding indicates that nesfatin-1 may play a role in 
atherosclerosis. Thus, nesfatin-1 is hypothesized to contribute 
to PAD development in T2DM 135. 
 
While the above studies determined nesfatin-1 in tissues, the 
identity of NUCB-2/nesfatin-1-expressing cells within the 
intestine is not known. Considering that nesfatin-1 is 
insulinotropic and considering incretins, which are predominant 
insulinotropins that are primarily secreted from the intestine, 
further research is warranted to determine whether nesfatin-1 
is present in enteroendocrine cells 136. 
 
3.2.4 Interleukin-7  
Interleukin-7 (IL-7) is a constitutively secreted cytokine 
primarily produced in bone marrow and peripheral lymphoid 
organs; it has recently been identified as a new adipokine 
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whose expression and secretion are increased in the obese 
human’s adipose tissue 31, 137. 
Whether this endogenous production of IL-7 has any 
physiological function in AT and metabolism remains unknown. 
IL-7 has been shown to induce the production of 
proinflammatory IL-1, IL-6, IL-8 and TNF-α by monocytes 31, 
138. 
 
3.2.5 Interleukin-10 
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that 
attenuates the inflammatory processes induced by TNF-α, IL-6 
and IL-1 while up-regulating the release of IL-1RA 139. IL-10 is 
negatively correlated with BMI, percent fat mass and fasting 
glucose levels 140. 
In another study, circulating levels of IL-10 were increased in 
obese people and were positively associated with weight, BMI, 
waist, waist-hip ratio, fat mass, systolic pressure and, 
interestingly, the titers of adenoviruses and enteroviruses 141. 
Low levels of IL-10 are associated with both the metabolic 
syndrome and type 2 diabetes. Although IL-10 is associated 
with insulin sensitivity, the mechanism of action is unknown. 
Weight loss is correlated with increased IL-10 plasma levels 
and reduced TNF-α and IL-6 plasma levels in obese subjects 
141. 
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3.3 Acute-phase proteins 
3.3.1 C-reactive protein 
C-reactive protein (CRP) was discovered as a substance in the 
sera of patients with pneumococcal pneumonia that reacted 
with polysaccharide C of Streptococcus pneumonia 142. 
Circulating CRP is synthesized and secreted predominantly by 
hepatocytes in response to proinflammatory cytokines such as 
TNF-α, IL-1 and IL-6 143, 144.  
 
CRP is a well-known marker of whole-body systemic low-grade 
inflammation, and data suggest that CRP is implicated in the 
development of cardiovascular disease 145. Increased levels of 
CRP are reported to be associated with metabolic syndrome, 
obesity, atherosclerosis, unstable angina, insulin resistance 
and diabetes 146. 
 
Higher levels of CRP are positively associated with measures 
of adiposity 147, whereas better fitness is associated with lower 
CRP in children and adults 148. 
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3.4 Omentin, a novel adipokine 
 
Figura  5. Omentin Molecule. Adapted from pdb.org 
Omentin/intelectin was initially described in intestinal Paneth 
cells; omentin/intelectin (Figure 5) associates with 
galactofuranose within the carbohydrate moieties of bacterial 
cell walls and has been implicated in the gut defensive 
mechanisms against pathogenic bacteria, for example, 
Escherichia coli 149. Additionally, a homolog of 
omentin/intelectin designated as omentin-2 has been reported, 
sharing 83% amino acid identity with omentin/intelectin.  
Omentin-1 is the major circulating form of omentin and has 
been predominantly studied by researchers. Its gene is located 
in the 1q22-q23 chromosomal region, which is considered to 
be linked to T2DM in various populations 150.  
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Omentin expression varies throughout the body (heart, lungs, 
ovary, placenta, endothelial cells, human epicardial fat, 
thymus, small intestine, colon and reticulocytes 151, 152; 
however, its main tissue of production is now considered to be 
visceral adipose tissue 153.  
Recently, omentin has been reported as a novel adipokine 
preferentially produced and secreted by visceral AT 
(predominantly expressed in AT stromal vascular cells) 
compared with subcutaneous AT; in vitro experiments revealed 
that omentin enhances insulin-stimulated glucose uptake in 
human adipocytes and triggers Akt signaling. Akt is a 
serine/threonine protein kinase that plays an important role as 
a second messenger in multiple cellular functions, for example, 
glucose metabolism, cell proliferation and apoptosis 153.  
 
3.4.1 Omentin and inflammation 
C-reactive protein and TNF-α-induced nuclear factor κ-light-
chain-enhancer of activated B cells (NFκB) activation in human 
endothelial cells are significantly decreased by omentin; 
moreover, the changes in CRP levels are predictive of 
changes in circulating omentin levels after metformin treatment 
in overweight, insulin-resistant women with polycystic ovary 
syndrome (PCOS), another chronic inflammatory disorder 154. 
Thus, omentin plausibly may have an anti-inflammatory role in 
proinflammatory states. Additionally, because omentin is 
mainly expressed in the stromal vascular cells of visceral 
adipose tissue, this potential anti-inflammatory role could be 
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important in modulating the proinflammatory elements in 
visceral AT. Future studies are needed to address this concept 
154. 
Omentin levels are decreased in the omental tissue in Crohn’s 
disease, which is an inflammatory disease resulting from a 
chronic transmural intestinal inflammatory state 151. Omentin is 
known to inhibit VCAM-1 expression induced by TNF-α, 
possibly demonstrating an anti-inflammatory role 155.  
Among other inflammatory conditions that have been studied is 
rheumatoid arthritis, in which low omentin levels were present 
in synovial fluid compared to healthy controls, indicating 
omentin-1 as a possible biomarker for the osteoarthritic 
degenerative process 156. The gene expression of omentin is 
enhanced in the airway epithelial cells of patients with asthma 
157. Lower levels of omentin in smokers appear to be related to 
a susceptibility to infections. Its levels in psoriasis are 
decreased, although increased levels of omentin are present in 
psoriatic arthritis 158. 
 
3.4.2 Omentin in obesity, diabetes and insulin 
resistance 
 
Omentin appears to enhance insulin-stimulated glucose uptake 
in cultured human adipocytes and may act as a modulator of 
vascular function 159. Additionally, circulating omentin levels 
and omental AT omentin mRNA expression were found to be 
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significantly lower in impaired glucose-tolerant (IGT) and 
T2DM subjects compared with matched controls 160. 
Circulating omentin and omentin gene expression in visceral 
AT were reported to be decreased in obese subjects. 
Moreover, circulating omentin levels were negatively correlated 
with markers of obesity, that is, body mass index, waist 
circumference and circulating leptin; thus, obesity and possibly 
leptin may regulate omentin levels 150.  
Circulating omentin levels have been reported to be 
significantly increased after weight loss induced by a 
hypocaloric diet; this finding was associated with a parallel 
improvement in insulin sensitivity 161. Furthermore, in human 
omental AT explants, insulin and glucose have been shown to 
decrease omentin mRNA expression, protein levels and 
secretion into conditioned media. Additionally, 
hyperinsulinemic induction via a prolonged insulin-glucose 
infusion in healthy subjects culminated in reduced circulating 
omentin levels 151.  
Interestingly, circulating omentin levels were elevated in 
patients with nonalcoholic fatty liver disease (NAFLD) and this 
feature was an independent predictor of hepatocyte ballooning. 
This observation is paradoxical considering that obesity is 
positively associated with NAFLD 162.  
 
3.4.3 Omentin and cardiovascular disease  
In an interesting study, the authors found reduced levels of 
omentin-1 in plasma and subcutaneous adipose tissue in 
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subjects with nascent metabolic syndrome versus controls, 
independent of obesity. The term nascent MetS was used by 
the authors to describe subjects with MetS without the 
confounding presence of diabetes and/or cardiovascular 
diseases. The presence of omentin deficiency in the syndrome 
further broadens the role of omentin as an anti-inflammatory 
adipokine 163. Circulating omentin concentration could be a 
useful marker of endothelial function as it was associated 
significantly with endothelial-dependent vasodilation 164.  
 
Shibata and coauthors have examined the presence and levels 
of omentin in patients with coronary artery disease (CAD) 
versus control subjects after adjustment for conventional CAD 
risk factors and suggested that omentin levels may serve as a 
novel biomarker for CAD, independently of the cardiovascular 
medication used 165. Omentin is expressed not only in visceral 
adipose tissue but also in epicardial adipose tissue, which is a 
potential explanation for its role in coronary artery disease 166.  
Thus, omentin-1 functions as an adipokine that attenuates 
vascular inflammation. Taken together, omentin-1 may 
modulate obesity-related metabolic and cardiovascular 
disorders via an anti-inflammatory mechanism 166.  
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3.5 Vaspin, a novel adipokine 
 
Figura  6. Vaspin Molecule. Adapted from uscnk.com 
One of the most recently discovered adipokines is vaspin 
(Figure 6), a VAT-derived serine protease inhibitor with insulin-
sensitizing effects, belonging to the serpin superfamily, clade A 
(Serpina12) 167. Vaspin is a novel 392–395-amino-acid 
adipokine that was identified in the visceral white adipose 
tissue of obese, diabetic Otsuka Long-Evans Tokushima fatty 
(OLETF) rats, an animal model characterized by central 
obesity and T2DM. In this experimental model, visceral vaspin 
expression and its plasma level were decreased with 
worsening of diabetes and body weight loss. Vaspin has also 
been demonstrated to improve glucose tolerance and insulin 
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sensitivity in diet-induced obese rodents and may also 
normalize altered gene expression related to insulin resistance 
167.  
Recombinant vaspin administration in DIO (diet-induced 
obesity) mice significantly improved their glucose tolerance 
and insulin sensitivity. This beneficial effect results in 
normalizing plasma glucose levels and modifying the 
expression of genes involved in the pathogenesis of insulin 
resistance, such as resistin, leptin, TNF-α, glucose transporter-
4 and adiponectin. Based on these data, it has been assumed 
that vaspin serves as an insulin sensitizer with anti-
inflammatory effects and might act as a compensatory 
mechanism with target white adipose tissue, which is activated 
in response to the decreased insulin sensitivity 167, 168.  
Nakatsuka et al have indicated that changes in the vaspin 
gene are responsible for its compensatory effects on the 
metabolic abnormalities with regard to obesity. They 
demonstrated that vaspin-transgenic mice were protected 
against diet-induced obesity, glucose tolerance impairment 
and fatty liver, whereas vaspin-deficient mice developed 
glucose intolerance due to up-regulation of the endoplasmic 
reticulum stress markers 169.  
Vaspin has been presented as a circulating serpin, which 
serves as a ligand for the cell-surface receptor complex 
GRP78/MTJ-1 in the liver after ER stress-induced translocation 
to the plasma membrane. Vaspin exerts its anti-inflammatory 
action through binding to GPR78, a glucose-regulated protein, 
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and the subsequent signals beneficially affect ER stress-
induced metabolic disorders 169. In another study, Nakatsuka 
et al demonstrated that vaspin served as a ligand for a cell-
surface GRP78/voltage-dependent anion channel complex in 
endothelial cells as well and thus exerts antiapoptotic, 
proliferative and protective effects on vascular walls in rat 
models with streptozotocin-induced diabetes mellitus 170. 
These reactions display the molecular basis of the direct 
correlation between this adipokine and the ER stress 
responses of endothelial cells and in the presence of obesity 
169, 170. Furthermore, vaspin protects endothelial cells via an 
inhibitory effect on NFkB 171. 
In human adipose tissue, vaspin mRNA expression was 
undetectable in lean individuals (BMI < 25 kg/m2), whereas it 
was fat depot-specific in obese subjects 172. Visceral vaspin 
mRNA expression positively correlated with BMI and 
percentage body fat and negatively correlated with plasma 
glucose concentration by a two-hour oral glucose tolerance 
test (OGTT). Subcutaneous vaspin mRNA expression 
negatively correlated with waist-to-hip ratio, fasting plasma 
insulin concentration and the glucose infusion rate during the 
steady state of euglycemic-hyperinsulinemic clamping. It has 
been suggested that the induction of vaspin mRNA expression 
in human adipose tissue might represent a compensatory 
mechanism associated with obesity, insulin resistance and 
T2DM 172. Blüher summarized the findings that vaspin is 
predominantly localized in mature adipocytes, isolated from 
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different fat depots, and is also expressed in skin, 
hypothalamus, pancreatic islets and gastric cells, whereas a 
stromal or vascular endothelial cell expression has not been 
established 173. 
 
3.5.1 Vaspin and metabolic syndrome 
Several studies have shown a positive correlation between 
vaspin gene expression and the components of the metabolic 
syndrome. Kloting et al have investigated vaspin mRNA 
expression as an indicator for obesity and its association with 
anthropometric and metabolic parameters in visceral and 
subcutaneous adipose tissue samples. Although vaspin has 
not been detected in white adipose tissue in individuals with 
normal weight, it has been established in both VAT and SAT in 
obese subjects with T2DM 174, 175. A significant correlation has 
been demonstrated between vaspin levels and obesity class, 
total body fat percentage, insulin resistance and glucose 
intolerance. Additionally, subcutaneous mRNA expression of 
vaspin significantly correlates with waist-hip ratio, 
immunoreactive insulin and the fasting glucose infusion rate in 
the steady-state condition. Contrary to expectations, vaspin 
mRNA expression has been found only in 23% of VAT and 
15% of SAT samples, and no significant correlation has been 
demonstrated between visceral vaspin gene expression and 
VAT and SAT areas 174. These findings are supported by 
another study that has reported vaspin mRNA expression 
predominantly in non-adipose cells 176. 
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3.5.2 Vaspin and cardiovascular disease 
VAT-derived factors, including adipocytokines such as vaspin, 
are believed to have local and endocrine roles in the 
development of initial and advanced atherosclerosis in obese 
subjects by affecting the endothelium, vascular smooth muscle 
cells and macrophages, thus disrupting vascular homeostasis 
177,178.  
Kobat et al have demonstrated lower vaspin levels in subjects 
with CAD compared to controls, and this tendency has been 
confirmed in a control group with higher systolic blood 
pressure in comparison to controls with normal blood pressure. 
Hence, vaspin might be used as a predictor of CAD 179. 
 
In females, Choi et al have indicated a significant correlation 
between plasma vaspin concentrations and the presence and 
severity of coronary stenosis, calculated by the Agatston score 
180. The results of Karbek et al and Esaki et al have confirmed 
the positive association between vaspin and coronary 
atherosclerosis 181. 
Cura et al have confirmed the absence of an association 
between vaspin levels and the severity of stenosis but have 
found elevated vaspin levels in subjects with acute ischemic 
stroke 182.  
Controversial results have been reported in two other studies, 
demonstrating that vaspin levels are significantly lower in 
subjects with CAD in comparison with healthy controls and 
correlate with CAD severity 179, 183. 
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4. Nonalcoholic fatty liver disease 
The healthy liver contains little fat, although up to 5-10% fat by 
histology is defined as normal. Once liver fat exceeds 5-10% 
and when this finding is not due to excess alcohol consumption 
or other known causes of liver disease, the condition is termed 
nonalcoholic fatty liver disease. NAFLD covers a spectrum of 
liver disease ranging from simple steatosis (SS) to 
nonalcoholic steatohepatitis (NASH), and cirrhosis due to 
NAFLD 184. 
NASH includes the presence of simple steatosis, lobular 
inflammation and hepatocellular injury 185, 186 (ballooning) with 
or without fibrosis. Whereas simple steatosis is generally a 
benign, non-progressive clinical entity, NASH may progress to 
cirrhosis 186. NAFLD is becoming an increasingly important 
health issue because it is the most common cause of chronic 
liver disease in the Western world, and its incidence is 
increasing rapidly 187.  
The insulin resistance associated with obesity and inactivity is 
characterized by multiple metabolic abnormalities, which are 
better predictors of cardiovascular disease and T2DM than 
obesity alone 188. A cluster of some of these features have 
been called metabolic syndrome. The liver fat accumulation 
due to non-alcoholic causes has an important role in the 
pathogenesis of insulin resistance and components of the 
metabolic syndrome 189. 
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NAFLD has been found to be associated with components of 
the metabolic syndrome (MetS) such as obesity, dyslipidemia, 
insulin resistance (IR) and T2DM 190, 191 and thought to 
represent the hepatic manifestation of MetS. Then, many 
people with NAFLD are not obese, and many people with 
NAFLD do not have diabetes. The presence and severity of 
NAFLD is an independent risk factor of cardiovascular and 
chronic kidney disease; suggesting that NAFLD is a 
multisystem disease (Table 1).  It is noteworthy that although 
the primary liver pathology in NAFLD affects hepatic structure 
and function, causing morbidity and mortality from cirrhosis, 
liver failure and HCC, the majority of deaths among NAFLD 
patients are attributable to cardiovascular disease (CVD) 192, 
193. 
Table 1. Histological scoring system. 
Conditions with 
established associations 
Conditions with  
emerging associations 
Obesity Polycystic ovary syndrome 
Insulin resistance Hypothyroidism 
Type 2 Diabetes Mellitus Obstructive sleep apnea 
Dyslipidemia Hypopituitarism      
Metabolic syndrome* Hypogonadism 
 Pancreato-duodenal resection 
*Metabolic syndrome, as defined by the Adult Treatment Panel 
(ATP) III criteria, is defined by the presence of three or more of the 
following: 1) waist circumference greater than 102 cm in men or greater than 88 
cm in women; 2) triglyceride level higher than 150 mg/dL (1.7 mmol/L) or drug 
treatment for elevated triglycerides; 3) high-density lipoprotein (HDL) cholesterol 
level lower than 40 mg/dL (1.03 mmol/L) in men and less than 50 mg/dL (1.29 
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mmol/L) in women or on drug treatment for low HDL; 4) systolic blood pressure ≥ 
130 mmHg or diastolic pressure ≥ 85 mmHg or treatment for hypertension; and 5) 
fasting plasma glucose level ≥ 110 mg/dL or drug treatment for elevated blood 
glucose Adapted from Grundy et al. Diagnosis and management of the 
metabolic syndrome: An American Heart Association/National Heart, Lung, 
and Blood Institute scientific statement. Circulation. 2005 25;112(17):2735-52. 
 
4.1 Epidemiology of NAFLD 
Epidemiology and natural history of NAFLD remain 
incompletely understood, with the incidence of fatty liver 
disease having been examined in only a few studies 194. The 
estimated prevalence of NAFLD varies widely, likely secondary 
to differences in the populations studied and the methods used 
to detect NAFLD. The prevalence of suspected NAFLD based 
on elevated aminotransferases without imaging is between 7% 
and 11% of the general population; however, this is likely an 
underestimation because aminotransferases may be normal in 
individuals with NAFLD 194. The prevalence based on 
abdominal ultrasound is between 20 and 30% of the population 
in the West, although the detection of steatosis by this 
technique requires fatty infiltration of at least one-third of the 
liver parenchyma 195. By liver biopsy, the prevalence of 
significant hepatic steatosis in potential living donors for liver 
transplantation was 20% 196. 
The prevalence of NAFLD worldwide varies between different 
countries and regions, which may be divided into three 
different groups of high, low and unknown prevalence 197. The 
high-prevalence group is mostly represented by "Western" 
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countries wherein the population has an “urban” lifestyle. The 
prevalence rates are persistently and rapidly increasing in 
these countries due to the increase in obesity, IR, lipid 
impairments and T2DM related to suboptimal dietary habits 
and sedentary lifestyles. The prevalence of NAFLD in these 
populations ranges from 20% to 30%, and the prevalence of 
NASH ranges from 3% to 16% 198. 
 
Ethnicity has a significant impact on the prevalence of NAFLD. 
In the Dallas Heart Study, the prevalence of hepatic steatosis 
was 45% in Hispanics, 33% in non-Hispanic Caucasians and 
24% in African Americans 199. This difference in prevalence 
was only partially explained by differences in obesity and 
insulin resistance, particularly in African Americans, in whom 
the prevalence of NAFLD was lower than in Caucasians with 
similar risk factors. This condition is highly prevalent in Asian 
populations as well. For example, in a Korean study of 
potential liver donors who underwent liver biopsy, the presence 
of NAFLD was 51%, with 10% having > 30% steatosis and 
2.2% having NASH 200. 
 
NAFLD tends to be more frequent in men than in women (42% 
versus 24%, respectively), although the frequency may be 
higher among postmenopausal women 201. The prevalence of 
NAFLD increases with age, from less than 20% in people 
under the age of 20 years to more than 40% in individuals over 
60 years. However, NAFLD has also been described in the 
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pediatric population with a prevalence of 2.6%, which may rise 
to within the range of 10–80% in obese children 202. 
A number of studies have examined the prevalence of NAFLD 
in patients attending obesity clinics or undergoing bariatric 
surgery and reported prevalence of NAFLD in these groups 
ranges from 57% to 91%, whereas the prevalence of NASH 
ranged from 26% to 37% and that of unsuspected cirrhosis 
from 1.6 to 1.7% 200, 203, 204.  
 
As a rule, the prevalence of NAFLD is higher in males and 
increases with increasing age, and it is influenced by the 
diagnostic method and the characteristics of the population, 
especially lifestyle habits. The prevalence of NAFLD is 80–
90% in obese adults, 30–50% in patients with diabetes and up 
to 90% in patients with hyperlipidemia 204. 
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4.2 Natural history of NAFLD 
 
The evolution of NAFLD requires years of follow-up and 
multiple biopsies 205. The majority of patients with simple 
steatosis will not develop NASH, approximately 5% of patients 
with NAFLD develop cirrhosis. Although the simple steatosis 
may not be totally benign, a percentage of patients will 
progress to NASH 206. However, patients with NASH are 
certainly at high risk for histologic progression and the 
development of cirrhosis. The age and degree of inflammation 
found in the initial liver biopsy are risk factors for progression 
to advanced fibrosis 207. Compared to simple steatosis, NASH 
has higher liver-related mortality with an odds ratio (OR) of 
5.71 for NASH and an OR of 10.06 for NASH with advanced 
fibrosis 208. Ekstedt et al, studied the natural history of NAFLD 
doing repeat biopsies, they reported that 47% of patients with 
SS progressed to NASH 209.  
The underlying mechanisms by which NASH or T2DM 
increase the risk of developing HCC are not fully understood; 
however, mechanisms involved in inflammation, metabolic 
stress and IR that are shared between NASH and T2DM may 
also be involved in HCC development 210. 
 
4.3 NAFLD diagnosis and staging 
Some patients undergoing thoracic and abdominal imaging for 
reasons other than liver symptoms, signs or biochemistry may 
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demonstrate unsuspected hepatic steatosis. While this 
phenomenon is not uncommon in clinical practice, studies 
have not systematically examined the characteristics or natural 
history of NAFLD in this patient population. The American 
Association for the Study of Liver Diseases (AASLD), the 
American College of Gastroenterology and the American 
Gastroenterological Association (AGA) published new 
guidelines for the diagnosis and management of NAFLD. They 
stipulated that the diagnosis of NAFLD requires 1) evidence of 
hepatic steatosis either by imaging or by histology, 2) the 
absence of significant alcohol consumption and 3) the absence 
of secondary causes of hepatic steatosis. Common alternative 
causes of hepatic steatosis are significant alcohol 
consumption, hepatitis C, medications, parenteral nutrition, 
Wilson’s disease and severe malnutrition 211. 
 
NAFLD should be suspected in individuals who are obese or 
diabetic or who have metabolic syndrome. However, NAFLD is 
frequently underdiagnosed because it is mostly asymptomatic. 
Several non-invasive methods are used to diagnose NAFLD. 
In clinical practice, plasma liver aminotransferase levels and 
ultrasound are the most common diagnostic techniques 204. 
Elevated alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels in the absence of other liver 
diseases may support NAFLD; moreover, an AST/ALT ratio 
less than 1 is also seen in NAFLD and supports NASH. Both 
aminotransferase levels and ultrasonography are widely 
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available, easy to perform and low in cost; however, they have 
low sensitivity for fatty liver. Other imaging techniques, such as 
computed tomography (CT) and nuclear magnetic resonance 
(MR) may also detect liver steatosis. CT provides a 
semiquantitative method and may be used to diagnose 
moderate to severe hepatic steatosis, although it has relatively 
low sensitivity and is not usually used for this purpose. MR 
remains the gold-standard technique: it is highly sensitive and 
specific for steatosis (with 5.5% intrahepatic TG content 
considered diagnostic for NAFLD), involves no radiation and 
allows quantification of liver steatosis; however, MR has limited 
availability and requires expensive hardware and software, 
rendering each test costly 204. Alternatively, the fatty liver index 
(FLI) is an algorithm based on four markers: body mass index, 
waist circumference, triglycerides and γ-glutamyltransferase 
(GGT); the FLI has been confirmed as accurately identifying 
NAFLD 212. 
 
Liver biopsy is currently the gold standard for characterizing 
liver histology (the degree of hepatocyte injury and the levels 
of fibrosis and inflammation) in NAFLD patients. However, this 
procedure is invasive and expensive and involves some 
morbidity and, very rarely, a mortality risk. Nevertheless, liver 
biopsy should be considered in those patients with fatty liver 
who, after imaging techniques, laboratory abnormalities and/or 
non-invasive methods, are considered to be at increased risk 
of having NASH and advanced fibrosis 213.  
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Because liver biopsy still remains the gold standard, a 
significant interest exists in developing non-invasive 
biomarkers for identifying steatohepatitis in NAFLD. In this 
regard, circulating levels of caspase-cleaved cytokeratin-18 
(CK-18) fragments have been investigated as a promising 
biomarker for the presence of steatohepatitis in patients with 
NAFLD 214. The number of hepatic progenitor cells and 
ductular reaction, assessed by CK-7 immunostaining, was 
used as an indicator of different fibrosis patterns in 38 pediatric 
NASH patients 215. Although the incidence of CK-7-positive 
centrilobular hepatocytes using immunostaining was 64.3% in 
14 needle biopsy liver specimens belonging to NASH patients, 
CK-7 immunostaining was not associated with the stage of 
fibrosis or the grade of steatosis. Significantly higher caspase 
3 and 8 activity was observed in patients with NASH than in 
simple steatosis in a small sample of 50 NAFLD patients. 
Mean caspase 3 and 8 activity scores were comparable 
between patients with normal and patients with elevated ALT 
levels 216. Moreover, recent breakthroughs have enabled non-
invasive techniques to be used to diagnose the level of 
fibrosis/inflammation (Figure 7).  
 
FibroScan, also known as transient elastography, is another 
non-invasive method for assessing liver fibrosis. This method 
measures liver stiffness, and although it was originally 
designed for the hepatitis C population, it is being used in the 
NAFLD population to determine the stage of fibrosis. However, 
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it has been shown to provide inaccurate liver stiffness 
measurement in overweight and obese patients 212.  
 
Figure 7. Diagnosis and staging of non-alcoholic fatty liver disease. 
Adapted from Schwenger K et al. Clinical approaches to NAFLD. World J 
Gastroenterol 2014; 20(7):1712-23. 
4.4 Histopathology of NAFLD 
Matteoni et al proposed important pathological classifications 
of NAFLD/NASH 217, the author distinguished between NASH 
and non-NASH. They defined histological NAFLD types 1 and 
2 as “non-NASH”, whereas types 3 and 4 were classified as 
NASH. Brunt et al 218 proposed a semiquantitative grading and 
staging system for NASH. The authors graded steatosis, 
inflammation and ballooning degeneration, and the staging 
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was based on the degree of fibrosis. This classification is only 
applicable to NASH and not to the entire spectrum of NAFLD. 
The pathology committee of the NASH CRN group therefore 
developed and validated a histological scoring system for use 
in NAFLD, based on Brunt’s classification. The NAFLD activity 
score (NAS) system is applicable to both adults and pediatric 
patients. The NAS represents the sum of the scores for 
steatosis (0–3), lobular inflammation (0–3) and ballooning 
degeneration (0–2). A NAS of 5 or more correlates with the 
diagnosis of NASH and scores less than 3 correlate with “not 
NASH”, whereas scores 3 or 4 are uncertain for the diagnosis 
of NASH. Fibrosis is scored separately to yield a fibrosis stage 
of between 0 and 4 206. 
The histologic spectrum of NAFLD is characterized by 
steatosis, lobular inflammation, ballooning of hepatocytes, 
fibrosis and other features that may or may not be present, 
such as Mallory-Denk bodies and portal inflammation.  
 
4.5 Pathogenesis of NAFLD 
 
The molecular mechanism underlying NAFLD progression has 
been interpreted in terms of a “double-hit” process, which was 
proposed in 1998 by Day et al 219. The “first hit” includes the 
accumulation of TG and free fatty acids (FFAs) in hepatocytes. 
Insulin resistance and hyperinsulinemia, it is associated with 
weight gain or obesity, this component of the “first hit” results 
in hepatic steatosis. These changes have been postulated as 
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resulting in increased sensitivity to the “second hit”, which 
involves proinflammatory cytokines, mitochondrial dysfunction, 
oxidative stress and subsequent lipid peroxidation, leading to 
hepatocyte damage, inflammation and the development of 
steatohepatitis, suggesting that in the “first hit”, TG 
accumulation predisposes to further liver damage in the 
pathogenesis of NASH. However, this theory has recently 
been replaced by a more complex model in which 1) hepatic 
TG accumulation appears to be a benign sign of hepatic 
steatosis, whereas FFAs and TG-derived metabolites may be 
the true lipotoxic agents that contribute to the development of 
NASH and 2) TG breakdown via metabolic lipases contributes 
to the pathogenesis and progression of NAFLD 220. 
 
The classic “two-hit” hypothesis has been modified into the 
“multiple parallel hits” hypothesis to explain the development of 
NAFLD and the progression from simple steatosis to NASH 221. 
In the “multi-hit” hypothesis, imbalanced lipid metabolism and 
insulin resistance are considered as the “first hit”, leading to 
the development of hepatic steatosis. After steatosis develops, 
the liver becomes more vulnerable to many hits that may act in 
parallel, including gut-derived bacterial toxins, 
adipokine/cytokine imbalance, mitochondrial dysfunction, 
oxidative damage, and dysregulated hepatocyte apoptosis, 
release of profibrogenic factors and proinflammatory mediators 
from impaired organelles, and hepatic stellate cell and Kupffer 
cell activation. These factors may collectively stimulate 
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inflammation, apoptosis, fibrosis and finally tumor 
development, Iron accumulation and genetic factors are also 
involved in the development of NASH.222, 223 (Figure 8). 
 
Figure 8. The multi-hit hypothesis of NAFLD pathogenesis. The “first 
hit”, insulin resistance and lipid metabolism dysregulation, leads to the development 
of simple steatosis and susceptibility of the hepatocytes to “multi-hits”. Adapted 
from Int. J. Mol. Sci. 2014;15,6184-6223. 
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4.6 Pathophysiological Mechanisms Leading to 
NAFLD 
 
4.6.1 Development of hepatic steatosis 
 
The unequivocal histologic hallmark of NAFLD in both adults 
and children is steatosis, defined as the histologic 
manifestation of intracytoplasmic hepatic lipid accumulation in 
the form of triglycerides. The generally accepted dogma in 
NAFLD pathogenesis is that TG accumulation occurs when 
hyperinsulinemia and insulin resistance, commonly 
associated with obesity and T2DM, are present 223. In NAFLD 
patients, the presence of IR is common at the liver, adipose 
tissue and muscle level 224. 
 
However, several mechanisms may lead to a fatty liver: 1) 
increased FFA supply due to increased lipolysis from both 
visceral/subcutaneous adipose tissue and/or increased intake 
of dietary fat, 2) decreased free fatty acid oxidation, 3) 
increased de novo hepatic lipogenesis (DNL) and 4) 
decreased hepatic very low-density lipoprotein-triglyceride 
secretion 225. Free fatty acid delivery to the liver accounts for 
almost two-thirds of its lipid accumulation 226. 
 
Elevated peripheral fatty acids and DNL therefore 
predominantly contribute to the accumulation of hepatic fat in 
UNIVERSITAT ROVIRA I VIRGILI 
NEW ADIPOKINES VASPIN AND OMENTIN, CIRCULATING LEVELS, GENE EXPRESSION IN ADIPOSE TISSUE AND RELATIONSHIP OF CIRCULATING LEVELS  WITH NONALCOHOLIC FATTY LIVER DISEASE 
David Gerardo Riesco Acevedo 
II. INTRODUCTION 
 
82 
 
 
NAFLD 227. Triglyceride synthesis appears to be an adaptive, 
beneficial response in situations where hepatocytes are 
exposed to potentially toxic triglyceride metabolites. Thus, 
evidence is increasing that the accumulation of fat in the liver 
in many instances cannot be regarded as pathology or disease 
but rather as a physiologic response to increased caloric 
consumption 228, 229, 230. 
Inflammation results in a hepatocyte stress response, which 
may lead to lipid accumulation and therefore could precede 
steatosis in NASH. Patients with NASH may present without 
any or much steatosis, suggesting that inflammation could 
occur first 231(Figure 9). 
 
 
 
 
Figure 9. Normal hepatic triglyceride synthesis and VLDL. Adapted 
from Brea A et all. Non-alcoholic fatty liver disease and cardiovascular risk. 
International Journal of Cardiology, 20 August 2013, Pages 1109–1117 
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Under IR conditions, the ability of insulin to stimulate liver 
glycogen synthesis and suppress hepatic glucose production 
(HGP) is diminished, resulting in increased plasma glucose 
concentrations 232. The adipose tissue becomes resistant to 
the antilipolytic effect of the insulin. Insulin fails to inhibit the 
hormone-sensitive lipase, the enzyme that regulates the 
release of FFA from adipose tissue, resulting in increased 
delivery of FFA to the liver 233, 234. Skeletal muscle IR typically 
accompanies insulin resistance at other sites. The independent 
effect of muscle insulin resistance on the exacerbation of 
NAFLD has been demonstrated in rodents 235, 236 and 
translated to humans, in which selective muscle insulin 
resistance in healthy young lean individuals has been shown to 
predispose them to increased hepatic de novo lipogenesis, 
hepatic TG accumulation and atherogenic dyslipidemia after 
consuming high-carbohydrate meals.  
 
4.6.2 Progression of steatosis to NASH 
 
In the process of developing NASH, multiple pathways or 
“multiple hits” are required to develop inflammation, cellular 
injury and fibrosis 223. ‘Hits’ that may contribute include direct 
hepatic lipotoxicity, oxidative stress, mitochondrial dysfunction, 
hepatocyte apoptosis, hepatic stellate cell and Kupffer cell 
activation, activation of profibrogenic factors and 
proinflammatory mediators, hormones derived from adipose 
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tissue (adipokines), endotoxins of intestinal origin, iron 
accumulation and genetic factors. All these mechanisms are 
not mutually exclusive, although they are more likely to act in a 
coordinated and cooperative manner 224. 
 
The current theory of lipotoxicity focuses on an increase in the 
flux of FFAs within hepatocytes, which is a direct consequence 
of an increased dietary intake of saturated fatty acids (SFAs), 
de novo lipogenesis and adipose tissue lipolysis in the setting 
of insulin resistance and impairment of compensatory oxidative 
processes. As a result, toxic lipid FFA-derived metabolites are 
generated, such as ceramides, diacylglycerols, 
lysophosphatidylcholine and oxidized cholesterol metabolites, 
which act as reactive oxygen species (ROS), causing lipotoxic 
hepatocellular injury manifested as endoplasmic reticulum 
stress, inflammation, apoptosis and necrosis 237 (Figure 10). 
 
Oxidative stress is a condition due to an altered balance 
between the production of ROS and the antioxidant defensive 
capacity. These cytotoxic ROS and lipid peroxidation products 
may diffuse into the extracellular space, affecting Kupffer cells 
and hepatic stellate cells (HSC) 238,239. 
 
This cellular oxidative stress from hepatocytes and the direct 
uptake of FFA or free cholesterol in Kupffer cells induces the 
activation of nuclear transcription factors such as NF-kβ, which 
regulates the synthesis of several proinflammatory cytokines, 
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such as 1) tumor necrosis factor-alpha, which activates the 
caspase pathway and leads to hepatocyte apoptosis, 2) 
transforming growth factor beta-1 (TGFβ-1), which activates 
collagen synthesis by HSC, 3) the Fas ligand that causes 
‘fratricide deaths’ between adjacent hepatocytes and 4) 
interleukin-8 (IL-8), a powerful neutrophil chemotactic 240. 
Endotoxin (lipopolysaccharide), a key constituent of many 
bacteria present in our microbiota, also considered a metabolic 
organ, plays a central role in innate immune responses and 
has been considered the so-called ‘‘second hit’’ in previous 
NASH models 219. Patients with NAFLD demonstrate increased 
gut permeability, which importantly has been associated with 
the severity of liver steatosis but not with the degree of NASH-
associated inflammation 241. 
 
Aron-Wisnewsky et al summarized the influence of gut 
microbiota in stimulating fat deposition and promoting NASH 
through five mechanisms: 1) it promotes obesity by improving 
the energy yield from food, 2) it regulates gut permeability, low-
grade inflammation and immune balance, 3) it modulates 
dietary choline metabolism, 4) it regulates bile acid metabolism 
and 5) it increases endogenous ethanol production by bacteria 
242. All these factors are molecular mechanisms by which 
microbiota may induce NAFLD and its progression. When tight 
junctions are impaired, intestinal permeability increases, 
leading to the delivery of gut-derived bacterial products such 
as endotoxin (LPS) to the liver via the portal vein. Ruiz et al 
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demonstrated that plasma endotoxin levels were elevated in 
fatty liver patients, which were further increased in individuals 
with NASH, and were associated with a rise in TNF-α gene 
expression in the hepatic tissue 243. 
Some studies have shown that increased hepatic iron 
concentration in patients with NAFLD is associated with IR and 
may therefore indirectly contribute to disease progression 244, 
245. Ferritin levels reflect total body iron stores, and as such, 
raised levels indicate iron overload. Studies suggest that 
ferritin may act as a cytokine to induce the release of further 
tissue cytokines and activate Kupffer and stellate cells, thereby 
exacerbating fibrosis 246, 247. 
 
Genetic factors might be attractive candidates to explain why a 
certain percentage of patients with fatty liver develop 
inflammation. NAFLD is a heritable disorder, suggesting 
genetic components exist that predispose to these traits. 
Polymorphisms in patatin-like phospholipase-3 (PNPLA-3), 
encoding a protein of unknown function with homology to lipid 
acyl hydrolases, have been strongly associated with increased 
hepatic fat content in NAFLD 248. 
Considering that NAFLD is part of a syndrome that strongly 
overlaps with obesity and insulin resistance, it therefore 
appears likely for common genetic aspects for all those 
diseases to exist 249. 
  
UNIVERSITAT ROVIRA I VIRGILI 
NEW ADIPOKINES VASPIN AND OMENTIN, CIRCULATING LEVELS, GENE EXPRESSION IN ADIPOSE TISSUE AND RELATIONSHIP OF CIRCULATING LEVELS  WITH NONALCOHOLIC FATTY LIVER DISEASE 
David Gerardo Riesco Acevedo 
II. INTRODUCTION 
 
87 
 
4.6.3 Role of adipokines in the pathogenesis of 
NAFLD 
 
Adipose tissue has been recognized in the last decade as a 
highly active endocrine and immune organ with the capacity to 
produce various mediators including adipocytokines and 
cytokines both in health and disease. The balance/imbalance 
of an adipose tissue ‘‘mediator cocktail’’ may profoundly affect 
not only the status of the adipose tissue but also particularly 
that of important target organs such as the liver 250. Adipokines 
have been reported as promoting insulin resistance 251,252, 
leading to enhanced delivery of FFA to the liver and then to 
hepatic steatosis. Moreover, these molecules may cause direct 
damage to the liver or act indirectly by increasing oxidative 
stress, liver fibrosis and tumor development by activating the 
oncogenic factor Stat3 221. 
 
Clinical studies suggest that the expression of adipokines may 
vary in patients with NAFLD/NASH compared to healthy 
controls. In particular, serum levels of proinflammatory 
adipokines such as leptin, resistin, visfatin, TNF-α and IL-6 are 
significantly higher in NAFLD/NASH patients, whereas levels 
of insulin-sensitizing adipokines with anti-inflammatory 
properties, such as adiponectin, are significantly reduced 253 
(Figure 10). Although adipose tissue secretes the majority of 
adipokines, they are also produced by other organs. In this 
regard, in human liver biopsies, hepatic adiponectin receptor 
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mRNA increased in biopsy-proven NASH 254. In contrast, 
Kaser S et al found low mRNA expression of adiponectin and 
adiponectin receptor 2 (AdipoR2) in the liver of patients with 
NASH compared to those with SS, and AdipoR2 expression 
was inversely related to alanine aminotransferase and the 
fibrosis stage 255. More recently, Moschen et al demonstrated 
in a prospective study that rapid weight loss after bariatric 
surgery results in a significant improvement of both histological 
and biochemical liver parameters, accompanied by an 
increase in adiponectin serum levels, as well as hepatic mRNA 
adiponectin expression 256. Hepatic TNF-α and TNF-α 
receptor-1 (TNFR-1) expression was increased in patients with 
NASH compared with an obese group of similar age without 
NASH. In these NASH patients, more advanced fibrosis was 
also accompanied by increased hepatic expression of TNF-α 
257.  
Regarding IL-6, Wieckowska et al demonstrated a marked 
increase in hepatic IL-6 expression in NASH patients 
compared to those with SS or a normal liver, and its 
expression positively correlated with the degree of 
inflammation, stage of fibrosis and IR 258. In another study, 
weight loss resulted in a dramatic decrease in hepatic IL-6 
expression 259. 
Recently, Chuan Shen et al have demonstrated that hepatic 
resistin overexpression in NASH patients is associated with the 
severity of liver inflammation and fibrosis 260. Finally, our 
research group has recently found serum and hepatic visfatin 
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to be higher in morbidly obese women with NAFLD than in 
those with normal liver histology 249. 
 
 
 
Figure 10. The multiple parallel hits model. Lipotoxicity: (1) A liver 
loaded with lipids consisting primarily of trigylcerides might reflect a benign process 
because trigylcerides might exert mostly protective effects. Furthermore, 
hyperleptinemia leads to oxidation of hepatic lipids, thereby also protecting this 
organ from lipotoxicity. When the capacity of peripheral and central organs of 
detoxifying ‘‘aggressive lipids’’ fails, lipotoxic attack of the liver might begin. 
Inflammation may precede steatosis in NASH. Gut-derived signals: Many signals 
beyond endotoxin might affect hepatic steatosis and inflammation. Several 
pathways have been identified how the gut microbiota might influence host energy 
metabolism: (2) Absence of the microbiota in germ-free mice correlates with 
increased activity of phosphorylated AMPK in the liver and the muscle (not shown). 
(3) Some of the breakdown products of polysaccharides are metabolized to SCFAs. 
SCFAs such as propionate and acetate are ligands for the G protein– coupled 
receptors Gpr41 and Gpr43. Shortage of SCFAs might allow the evolution of 
systemic inflammatory events. Such mechanisms elegantly combine diet, 
microbiota, and the epithelial cell as ‘‘nutrient sensor.’’ (4) The microbiota decreases 
epithelial expression of fasting-induced adipocyte factor (Fiaf), which functions as a 
circulating lipoprotein lipase (LPL) inhibitor and therefore is an important regulator of 
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peripheral fat storage.(5) Several TLRs, such as TLR5 or TLR9, are not only able to 
affect microbiota but also to regulate metabolism, systemic inflammation, and insulin 
resistance, thus highlighting the role of the innate immune system in metabolic 
inflammation as observed in NASH. (6) Various nutrients such as trans fatty acids 
(TFAs), fructose or aryl hydrocarbon receptor (AhR) ligands such as 2,3,7,8-
tetrachlorodibenzodioxin (TCDD) may directly lead to steatosis/liver inflammation. 
Adipose tissue–derived signals: Signals derived from the adipose tissue beyond 
toxic lipids might play a central role in NAFLD/NASH. (7) Here, adipocytokines such 
as adiponectin and leptin, certain proinflammatory cytokines such as TNFa or IL-6, 
and others (the death receptor Fas, PPARc) are of key relevance. The 
cytokine/adipocytokine milieu might be critical because ob/ob-adiponectin tg mice, 
although becoming severely obese, are not insulin-resistant. This suggests that in 
the hierarchy of processes soluble mediators play the central role. Adipose-derived 
mediators might indeed affect target organs such as the liver, because JNK1 
adipose-deficient mice are protected from diet-induced obesity, and experiments 
have demonstrated that this effect is mediated mainly by IL-6 (a cytokine), which is 
of key importancein human obesity. Adapted from Herbert Tilg and Alexander R. 
Moschen. Evolution of Inflammation in Nonalcoholic Fatty Liver Disease: The 
Multiple Parallel Hits Hypothesis. HEPATOLOGY, Vol. 52, No. 5, 2010.
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Considering that: 
 
1. In humans, the ability of different tissues, such as 
adipose tissue, to secrete omentin, vaspin and other 
adipokines has been demonstrated. 
 
2. The available data associate circulating levels of 
omentin and vaspin, and circulating levels of other 
proinflammatory and anti-inflammatory adipocytokines, 
with the presence and degree of obesity. However, 
references regarding the relationship between the 
circulating levels of omentin/vaspin and gene expression 
in adipose tissue are scarce and sometimes 
contradictory. 
 
3. Recently available data associate circulating levels of 
omentin/vaspin with different metabolic syndrome 
parameters and the presence of its hepatic 
manifestation: nonalcoholic fatty liver disease. The 
associations between the circulating levels of 
omentin/vaspin and the presence and histological type 
of nonalcoholic liver disease, that is, simple steatosis 
(SS) or nonalcoholic steatohepatitis (NASH), are poorly 
studied. 
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4. Liver biopsy is the current gold standard to diagnose, 
monitor progress and determine prognosis of 
nonalcoholic fatty liver disease. At present, there is no 
clinical or biochemical marker, or any validated 
mathematical model, which by combining clinical and 
biochemical data, would quantify the probability of 
having histologically advanced nonalcoholic fatty liver 
disease, or its progression from simple steatosis to 
NASH.  
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The objectives of this study are as follows: 
 
1. To analyze the circulating levels of omentin and vaspin 
and their gene expression in visceral and subcutaneous 
adipose tissue in a group of morbidly obese women 
versus a control group of normal-weight women and to 
study their relationship with the different clinical-
biochemical variables that constitute metabolic 
syndrome. 
 
2. To analyze the relationship between the circulating 
levels of omentin/vaspin and gene expression in 
subcutaneous and visceral adipose tissue with the 
presence of type 2 diabetes mellitus and insulin 
resistance in a group of morbidly obese women. 
 
3. To analyze the relationship between circulating levels of 
omentin/vaspin and the presence of nonalcoholic fatty 
liver disease in a group of morbidly obese women. 
 
4. To evaluate the clinical use of the determination of 
circulating levels of omentin and vaspin as biomarkers 
for the presence and stage of nonalcoholic fatty liver 
disease. 
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1. Patients and methods 
 
The study was approved by the institutional review board. All 
participants gave written informed consent for participation in 
the medical research. We analyzed the circulating levels of 
vaspin and omentin in 71 Spanish women of European 
descent: 31 were lean (BMI < 25 kg/m2) and 40 were morbidly 
obese (BMI > 40 kg/m2). We also analyzed vaspin and omentin 
gene expression in paired samples of subcutaneous and 
visceral adipose tissues from 46 patients: 6 were lean (BMI < 
25 kg/m2), and 40 were morbidly obese (BMI > 40 kg/m2). We 
additionally analyzed 40 liver samples from MO women. 
NAFLD was diagnosed by the following criteria: 1) liver 
pathology, 2) an intake of less than 10 g of ethanol/day and 3) 
appropriate exclusion of other liver diseases.  
 
Adipose tissue samples were obtained from morbidly obese 
women and from control women who underwent bariatric 
surgery by laparoscopic gastric bypass and elective surgery, 
respectively. Subcutaneous adipose tissue biopsies were 
obtained from the right hypochondrion region and visceral 
adipose tissue biopsies were obtained from the greater 
epiploon region. The liver biopsies were also obtained during 
the planned bariatric surgery. All liver biopsies were performed 
under clinical indications.  
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For each type of surgery, the samples were obtained by the 
same specialist. Morbidly obese women and controls had 
similar ages. The weight of all subjects was stable for at least 
three months before surgery. The exclusion criteria were as 
follows: 1) concurrent use of medications known to produce 
hepatic steatosis, 2) patients using lipid-lowering medications 
including PPAR-α or -γ agonists, 3) diabetic women who were 
receiving insulin or on medication likely to influence 
endogenous insulin levels, 4) menopausal and post-
menopausal women and subjects receiving contraceptive 
treatment and 5) patients who had an acute illness, current 
evidence of acute or chronic inflammatory or infectious 
diseases or end-stage malignant diseases. 
 
The liver samples were scored by two experienced 
hepatopathologists using the methods described previously 261, 
262. 
According to their liver pathology, the patients were 
subclassified into the following groups: 1) MO with normal liver 
(NL) histology (n = 4), 2) MO with simple steatosis 
(micro/macrovesicular steatosis without inflammation or fibrosis 
(n = 18) and 3) MO with nonalcoholic steatohepatitis (NASH) 
(Brunt grade 1–3, n = 18). 
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2. Laboratory methodology 
2.1 Anthropometric measurements 
BMI was calculated as weight divided by height squared 
(kg/m2) according to the criteria of the World Health 
Organization 2. Waist circumference was measured at the 
height of the iliac crest.  
Morbidly obese women were further subclassified according to 
the presence or absence of the metabolic syndrome. The MetS 
and metabolic risks are defined according to the US National 
Cholesterol Education Program Adult Treatment Panel III 
guidelines and modified as recommended in the latest 
American Heart Association/National Heart, Lung, and Blood 
Institute Scientific Statement by adopting a lower cutoff for 
fasting glucose (5.6 mmol/L). MetS was defined as having 
three of the following metabolic risk factors: 1) central obesity 
(waist circumference 88 cm in women), 2) hypertriglyceridemia 
(fasting triglycerides 1.69 mmol/L (150 mg/dL)), 3) low HDL 
cholesterol (fasting HDL < 1.29 mmol/L (50 mg/dl) in women), 
4) glucose intolerance (fasting glucose 5.6 mmol/L (100 
mg/dL)) and 5) hypertension (blood pressure 130/85 mmHg 
obtained as the mean of two seated readings obtained after 
resting for at least 10 minutes or on regular antihypertensive 
medications) 262. 
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2.2 Analytical methods 
2.2.1 Biochemical and immunoanalysis 
Basal, fasting blood samples were drawn after an overnight 
fast to determine glucose, insulin and standard laboratory 
parameters. Plasma and serum samples were stored at -80°C 
until analytical measurements were performed except for 
glucose, which was determined immediately after the blood 
was drawn. 
Fasting plasma glucose and lipid profile (triglycerides, total 
cholesterol and high-density lipoprotein cholesterol) were 
measured using the usual enzymatic methods in an ADVIA 
Centaur autoanalyzer. Low-density lipoprotein cholesterol was 
calculated as the difference between the total cholesterol, HDL 
and triglyceride content/5 when TG was < 400 mg/dL. The 
plasma insulin concentration was measured by commercial 
chemiluminescence assay for ADVIA Centaur (Siemens 
Medical Solutions S. L., Barcelona, Spain) according to the 
manufacturer’s instructions. The homeostasis model 
assessment of insulin resistance (HOMA2-IR) was completed 
using the HOMA Calculator version 2.2.2 
(http://www.dtu.ox.ac.uk, accessed May 2010). Glycosylated 
hemoglobin (HbA1c) was measured by a chromatographic 
method (Glico Hb Quick Column Procedure, Helena 
Laboratories, Beaumont, TX, USA). Circulating levels of TNFR-
1, TNFR-2 (Biosource Europe S.A., Nivelles, Belgium), IL-6 
(Quantikine, R&D Systems, Minneapolis, MN, USA), 
adiponectin, HMW adiponectin (Linco Research, Inc., St. 
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Charles, MO, USA), resistin (Biovendor, Modrice, Czech 
Republic), leptin (Biovendor, Modrice, Czech Republic), RBP-4, 
lipocalin-2 (Biovendor, Modrice, Czech Republic), serum 
vaspin (Adipogen, Seoul, South Korea) and plasma omentin 
(Apotech, Axxora, Nottingham, UK) were measured in 
duplicate using enzyme-linked immunosorbent assays (ELISA) 
following the manufacturer’s instructions. The TNFR-1 assay 
sensitivity was 50 pg/mL, and the interassay and intra-assay 
coefficients of variation were less than 5.7 and 1.7%, 
respectively. The TNFR-2 assay sensitivity was 0.1 ng/mL, and 
the interassay and intra-assay coefficients of variation were 
less than 3.2 and 3.3%, respectively. The IL-6 assay sensitivity 
was 0.039 pg/mL, and the interassay and intra-assay 
coefficients of variation were less than 9.6 and 6.9%, 
respectively. The adiponectin assay sensitivity was 0.78 ng/mL, 
and the interassay and intra-assay coefficients of variation 
were less than 8.4 and 7.4%, respectively. The HMW 
adiponectin assay sensitivity was 0.5 ng/mL, and the 
interassay and intra-assay coefficients of variation were less 
than 3.8 and 2.6%, respectively. The resistin assay sensitivity 
was 33 pg/mL, and the interassay and intra-assay coefficients 
of variation were less than 6.9 and 3.4%, respectively. The 
leptin assay sensitivity was 0.2 ng/mL, and the interassay and 
intra-assay coefficients of variation were less than 7.6 and 
4.4%, respectively. The RBP-4 assay sensitivity was 0.02 g/L, 
and the interassay and intra-assay coefficients of variation 
were less than 1.1 and 2.2%, respectively. The LCN-2 assay 
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sensitivity was 0.01 ng/mL, and the interassay and intra-assay 
coefficients of variation were less than 5.6 and 4.4%, 
respectively. The vaspin assay sensitivity was 12 pg/mL, and 
the interassay and intra-assay coefficients of variation were 
less than 6 and 4%, respectively. The omentin assay sensitivity 
was 0.4 ng/mL, and the interassay and intra-assay coefficients 
of variation were less than 6 and 2.7%, respectively. 
 
 
2.2.2 Analysis of Human Vaspin and Omentin 
Gene Expression  
Total RNA was isolated from adipose tissues using the RNeasy 
mini kit (Qiagen) according to the manufacturer’s protocol and 
digested with DNase I (RNase-Free DNase set, Qiagen). RNA 
quality was evaluated by measuring the 260/280-nm 
absorbance ratio (≥ 1.8) and by electrophoresis. First-strand 
cDNA was synthesized using an equal amount of total RNA 
with the High Capacity RNA-to-cDNA Kit (Applied Biosystems). 
Real-time quantitative PCR was performed in a final volume of 
20 μL, which contained 10 ng of reverse-transcribed cDNA, 10 
μL of 2X Taq Man Fast Universal PCR Master Mix (Applied 
Biosystems) and 1 μL Taq Man Assay predesigned by Applied 
Biosystems® for the detection of vaspin, omentin and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), used 
as a housekeeping gene. All reactions were performed in 
triplicate and were carried out in 96-well plates by using the 
7900HT Fast Real-Time PCR system (Applied Biosystems).  
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2.3 Statistical analysis 
All the values reported are expressed as the means ± SEM 
(standard error of the mean) or as means ± SD (standard 
deviation) and were analyzed using the statistical package 
SPSS/PC+ for Windows (v.20.0, Chicago, IL, USA). One-way 
ANOVA with post-hoc Tukey test was used to compare 
continuous variables between groups. The strength of 
association between variables was calculated using Pearson’s 
method and Spearman’s ρ-correlation test. Multiple linear 
regression analysis with backward variable selection was 
performed to identify independent predictors of HOMA2-IR. 
The validity of the regression model and its assumptions was 
assessed with the plot of residuals vs predicted values. The 
data were normally distributed. Logistic regression analysis 
was performed to identify independent predictors of the 
metabolic syndrome. Vaspin and omentin circulating levels 
were age- and BMI-adjusted in some analyses. P values < 0.05 
were considered to be statistically significant. 
ROC curves were used to evaluate the biomarker performance 
of circulating omentin levels in the diagnosis of NAFLD and 
NASH compared to liver biopsy, which is the current reference 
method. The three values of optimum cutting were selected 
based on obtaining a first cutoff of high sensitivity (90%), a 
second cutoff that prioritized specificity (90%) and a third that 
included the best combination of sensitivity and specificity 
according to the Youden index.  
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1. Serum vaspin and omentin levels in normal-
weight and morbidly obese women 
 
Table 2 shows the baseline characteristics of the group of 
control women with normal weight (BMI < 25 kg/m2) and the 
group of morbidly obese women (BMI > 40 kg/m2). The two 
groups exhibited similar ages.  
 
Patients from the MO group showed a significant increase in 
glucose, insulin, HOMA2-IR and glycosylated hemoglobin A1c 
compared to the control group. Blood pressure was increased 
in the MO group.  
 
The lipid profile significantly differed in the two groups with high 
triglyceride levels in the MO group and significantly decreased 
HDL-C levels in MO women compared to the control group.  
Applying the metabolic syndrome ATP III criteria 262, 86% of 
MO women met the criteria, compared with 2.5% of women in 
the control group. In the statistical analysis, a significant 
increase was evident in the circulating levels of AST, ALT and 
GGT in the subgroup of MO women. 
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Mean (SEM) * Significant differences vs the control group (p < 0.05) 
 
 
 
 
CONTROL 
(N = 31) 
MORBID 
OBESITY 
(N = 40) 
P 
VALUE 
 
Age (years) 45.53 (1.55) 46.37 (3.34) ns 
Weight (kg) 56.90 (6.96) 122.28 (17.07) <0.001 
BMI (kg/m²) 23.21 (0.46) 48.22 (1.07) <0.001 
WC(cm) 80.40 (2.16) 134.00 (3.10) <0.001 
SBP(mmhg) 120.91 (4.22) 134.99 (4.07) 0.020 
DBP(mmhg) 70.04 (1.96) 76.70 (2.80) <0.001 
Glucose(mg/dl) 94.06 (2.53) 117.70 (4.25) 0.001 
Insulin(mu/l)  8.25 (1.32) 22.69 (3.94) 0.001 
Hba1c (%) 4.55 (0.07) 5.63 (0.29) <0.001 
HOMA2-IR 1.11 (0.18) 2.60 (0.24) 0.001 
HDL-C (mg/dl) 59.83 (2.87) 40.97 (1.33) <0.001 
Triglycerides (mg/dl) 95.13 (9.06) 185.52 (11.88) <0.001 
AST (u/l) 21.36 (7.56) 46.08 (32.97) <0.001 
ALT (u/l) 20.08 (13.79) 44.48 (25.85) <0.001 
GGT(u/l) 20.59 (29.68) 32.63 (33.82) ns 
FA (u/l) 61.58 (20.50) 71.47 (21.01) 0.022 
Table 2. Baseline characteristics of the study cohort 
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The circulating levels of adipocytokines studied, comparing 
both groups, are shown in Figure 11.  
Regarding the analysis of serum vaspin levels depending on 
the degrees of obesity, the mean serum vaspin±SD was 
0.87±0.96 µg/L in MO women and 1.66±2.09 µg/L in the control 
group; statistical analysis showed no significant differences of 
the MO group compared to the control group. 
The analysis of circulating omentin levels in the MO group 
showed significant differences from the control group: in the 
MO group, the mean±SD was 1.97±2.15 ng/ml; in the control 
group, 5.27±5.33 ng/ml.  
 
 
 
Figure 11 Vaspin and omentin concentrations in control women and 
morbidly obese women. * Indicates statistically significant differences 
between groups (p < 0.05). 
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2. Correlation of circulating levels of vaspin and 
omentin with metabolic variables and circulating 
levels of other adipocytokines.  
No correlation was observed between serum vaspin levels and 
the metabolic variables studied (Table 3). The relationship 
between serum vaspin levels and the presence of MetS 
diagnostic criteria was also studied; however, we were unable 
to show correlation between the two.  
 
 
Table 3. Correlation of vaspin and omentin levels with 
metabolic variables  
 
 
 
 
Circulating levels VASPIN OMENTIN 
Variables r p-value r p-value 
BMI (Kg/m²)  -0.181 0.134 -0.212 0.096 
WC (cm) -0.448 0.007 -0.332 0.078 
Glucose (mg/dL) -0.002 0.989 -0.276 0.029 
Insulin (mU/L) -0.015 0.903 -0.252 0.054 
HOMA2-IR 0.004 0.976 -0.274 0.037 
HbA1c (%) -0.181 0.218 0.011 0.943 
HDL-C (mg/dL) 0.166 0.183 -0.178 0.182 
Triglycerides (mg/dL) -0.218 0.072 -0.101 0.433 
SBP (mmHg) -0.002 0.986 -0.179 0.201 
DBP (mmHg) -0.019 0.887 -0.072 0.608 
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BMI: body mass index, WC: waist circumference, HOMA2-IR, 
homeostasis model assessment of insulin resistance; HDL-C: high-
density lipoprotein cholesterol, SBP: systolic blood pressure, DBP: 
diastolic blood pressure. Bolded p-values indicate significant 
correlations (p < 0.05). 
 
However, serum vaspin levels correlated inversely with serum 
lipocalin-2 and IL-6 leptin levels (Table 4).  
 
Table 4. Correlation of vaspin and omentin levels with 
circulating adipo/cytokine levels 
 
Circulating levels VASPIN OMENTIN 
Variables r p-value r p-value 
HMW Adiponectin (µg) 0.178 0.173 0.078 0.557 
Adiponectin  (µg/L) 0.145 0.250 0.013 0.431 
Resistin (µg/L) -0.178 0.157 -0.150 0.236 
LCN-2 (µg/L) -0.336 0.016 0.088 0.559 
IL-6 (ng/L) -0.290 0.029 0.033 0.812 
RBP-4 (mg/dL) 0.015 0.915 0.013 0.931 
TNFR-1 (µg/L) -0.241 0.057 0.004 0.976 
TNFR-2 (µg/L) -0.051 0.689 0.036 0.787 
Leptin (µg/L) -0.290 0.041 0.195 0.199 
 
HMW adiponectin: high-molecular-weight adiponectin, LCN-2: 
lipocalin-2, IL-6: interleukin-6, RBP-4: retinol-binding protein-4, 
TNFR-1: tumor necrosis factor receptor-1, TNFR-2: tumor necrosis 
factor receptor-2. Bolded p-values indicate significant correlations (p 
< 0.05). 
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The omentin plasma levels were inversely correlated with 
glucose and HOMA2-IR levels (Table 3). When the relationship 
between the circulating levels of omentin and the presence of 
metabolic syndrome diagnostic criteria was investigated, a 
negative correlation with the metabolic syndrome was 
demonstrated. After adjusting for age and BMI, the sample 
subjects were subclassified into three tertiles according to their 
omentin levels: tertile 1 (> 4.33 ng/ml), tertile 2 (2.30 to 4.33 
ng/ml) and tertile 3 (< 2.30 ng/ml). In logistic regression 
analysis, low circulating omentin levels in tertiles 2 and 3 were 
associated with the presence of metabolic syndrome diagnostic 
criteria, whereas tertile 1 patients with higher omentin levels 
were not related to the development of MetS (Table 5). 
 
Table 5. Logistic regression analysis for the presence of the 
metabolic syndrome according to the omentin tertile circulating 
levels 
 
 OR 95% CI p-value 
OMENTIN tertile 2 vs 1 25.00 4.41 – 141.68  <0.001 
OMENTIN tertile 3 vs 1 90.00 11.46 – 706.71 <0.001 
 
Model 1. Omentin tertiles (ng/ml) adjusted for BMI and age: 1 (> 
4.33); 2 (4.33–2.30); 3 (< 2.30). Tertile 1 as reference with OR = 1. 
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In considering whether a correlation existed between omentin 
plasma levels and circulating levels of other adipocytokines, no 
correlation could be established (Table 6). 
 
Table 6 Correlations between the number of diagnostic criteria 
of metabolic syndrome met by the patients 
 
 
Variables 
Number of criteria of Metabolic 
syndrome 
r p-value 
Vaspin (µg/L) -0.209 0.83 
Omentin (µg/L) -0.264 0.045 
BMI (Kg/m²) 0.737 <0.001 
WC (cm) 0.783 <0.001 
HOMA2-IR  0.589 <0.001 
Glucose (mg/dl) 0.710 <0.001 
SBP (mmHg) 0.636 <0.001 
DBP (mmHg) 0.250 0.006 
HDL-C (mg/L) -0.750 <0.001 
Triglycerides (mg/dl) 0.704 <0.001 
 
Vaspin and omentin circulating levels and different parameters. BMI: 
body mass index, WC: waist circumference, HOMA2-IR: 
homeostasis model assessment of insulin resistance, SBP: systolic 
blood pressure, DBP: diastolic blood pressure. Bolded p-values 
indicate significant Spearman’s correlations (p < 0.05). 
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3. Vaspin gene expression in subcutaneous and 
visceral adipose tissue in normal-weight and 
morbidly obese women.  
In a second part of the study, the gene expression of 
adipokines was analyzed in subcutaneous and visceral adipose 
tissues, comparing the morbidly obese group (n = 40) with the 
control group of normal-weight individuals (n = 6). The results 
are shown in Figure 12. A significant increase in vaspin gene 
expression was shown in both subcutaneous and visceral 
adipose tissues in the MO group compared to the control 
group. No differences were found between vaspin gene 
expression in visceral and subcutaneous adipose tissues in 
individuals of the MO group (p = 0.192) compared with the 
control group (p = 0.934).  
Vaspin gene expression in both types of subcutaneous and 
visceral adipose tissues is not correlated with obesity, glucose 
metabolism, insulin resistance parameters, blood pressure and 
other adipokines or the inflammatory parameters studied (data 
not shown). 
 
4. Omentin gene expression in subcutaneous and 
visceral adipose tissues in normal-weight and 
morbidly obese women. 
Gene expression (mRNA) in subcutaneous adipose tissue was 
similar in the morbidly obese group and the control group. 
However, the present study demonstrated that omentin gene 
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expression in visceral adipose tissue was significantly lower in 
morbidly obese individuals compared to normal-weight 
controls. When comparing both adipose tissues, omentin gene 
expression was observed to be higher in visceral adipose 
tissue relative to its gene expression in subcutaneous tissue in 
both the MO (p = 0.009) and control (p = 0.034) groups.  
 
 
 
Figure 12. mRNA Vaspin and omentin expression in visceral and 
subcutaneous adipose tissue. 
 
Omentin mRNA gene expression in both visceral and 
subcutaneous adipose tissues was not correlated with obesity, 
glucose metabolism or insulin resistance parameters. No 
relationship could be established for either of the two types of 
adipose tissue between omentin gene expression and lipid 
metabolism, blood pressure and other adipokines or the 
cytokines studied (data not shown).   
 
UNIVERSITAT ROVIRA I VIRGILI 
NEW ADIPOKINES VASPIN AND OMENTIN, CIRCULATING LEVELS, GENE EXPRESSION IN ADIPOSE TISSUE AND RELATIONSHIP OF CIRCULATING LEVELS  WITH NONALCOHOLIC FATTY LIVER DISEASE 
David Gerardo Riesco Acevedo 
V. RESULTS 
 
118 
 
5. Serum omentin and vaspin in morbid obesity in 
relation to the presence and histologic type of 
nonalcoholic fatty liver disease. 
The circulating levels of vaspin and omentin and their 
association with NAFLD and the histologic type, that is, hepatic 
simple steatosis (SS) and nonalcoholic steatohepatitis, were 
studied in the group of morbidly obese women. Liver tissue 
samples of MO patients were classified according to 
histological criteria into two subgroups: normal liver (NL) (4 
cases) and NAFLD (36 cases). At the baseline analysis of both 
groups, a significant increase in AST, ALT and GGT levels was 
observed in the group with liver disease (NAFLD) with respect 
to the subgroup of patients without impaired liver histology 
(NL). No differences were observed between the two groups 
with respect to the other parameters analyzed: age, weight, 
BMI, SBP, DBP, fasting glucose, fasting insulin, HbA1c, 
HOMA2-IR, HDL-C and TG (Table 7). 
 
  
UNIVERSITAT ROVIRA I VIRGILI 
NEW ADIPOKINES VASPIN AND OMENTIN, CIRCULATING LEVELS, GENE EXPRESSION IN ADIPOSE TISSUE AND RELATIONSHIP OF CIRCULATING LEVELS  WITH NONALCOHOLIC FATTY LIVER DISEASE 
David Gerardo Riesco Acevedo 
V. RESULTS 
 
119 
 
Table 7. Baseline characteristics of the morbidly obese women 
based in liver histology 
MORBID OBESITY 
 NORMAL LIVER 
(n=4) 
NAFLD (n=36) p-value 
AGE (years) 44.05 (10.71) 47.55 (11.11) n.s 
WEIGHT (Kg) 122.62 (15.43) 122.79 (18.14) n.s 
BMI (Kg/m2) 48.46 (7.33) 48.02 (5.66) n.s 
PC (cm) 133.85 (14.90) 132.48 (11.54) n.s 
TAs (mmHg) 134.00 (15.58) 133.66 (26.34) n.s 
TAd (mmHg) 76.38 (15.69) 78.99 (17.73) n.s 
GLUCOSA(mg/dL) 103.11 (27.96) 119.06 (38.61) n.s 
INSULINEMIA(Mu/L) 17.48 (11.19) 21.24 (22.73) n.s 
HbA1C (%) 5.30 (0.80) 6.14 (1.82) n.s 
HOMA2-IR 2.13 (1.31) 2.74 (2.75) n.s 
HDL-C (mg/dL) 40.02 (9.68) 41.21 (8.10) n.s 
TRIGLIC (mg/dL) 158.32 (44.76) 165.70 (73.56) n.s 
AST (U/L) 31.91 (11.01) 48.58 (27.03) * 0.004 
ALT (U/L) 32.47 (11.79) 48.11 (27.31) * 0.005 
GGT (U/L) 19.94 (10.40) 38.01 (24.90) * 0.025 
FA (U/L) 65.35 (18.92) 75.29 (22.62) n.s 
 
Mean standard deviation. Comparison between the subgroup with 
normal liver and NASH subgroup. * Significant differences p <0.05. 
 
 
The comparison study and analysis of the circulating levels of 
adipocytokines, between the two subgroups (NL and NAFLD) 
showed that the circulating omentin levels tended to be higher 
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in the subgroup of MO women whose liver histology was 
indicative of NAFLD compared with MO women having normal 
liver histology. However, these differences were not significant 
considering the n of the normal liver group (NL MO: 0.38±0.43, 
NAFLD MO: 1.81±2.04). Because this trend was observed, 
serum omentin levels were studied in the different liver 
histology subgroups of NL, SS and NASH. The omentin plasma 
levels were statistically higher in the NASH group compared to 
the SS group (SS MO: 1.07±1.52, NASH MO: 2.30±2.03). 
When analyzing serum vaspin levels, no significant differences 
were identified by liver histology type (NL MO: 0.76 ± 1.11, SS 
MO: 0.85 ± 1.18, NASH MO: 1.26±0.95). 
Regarding the rest of the adipokines studied, no significant 
differences were observed (data not shown). 
 
6. Assessment of the omentin effect on the 
presence of NASH  
According to the previous results, this study evaluated the 
diagnostic efficacy of omentin plasma levels as a biomarker of 
NAFLD in the group of MO patients with liver histology 
indicative of NAFLD; additionally, it evaluated the behavior of 
omentin plasma levels in the NASH subgroup, determining a 
cutoff point and area under the curve to establish the diagnosis 
of both entities (Figure 13).  
Regarding NAFLD, the area under de curve of omentin 
circulating levels was 0.64. Therefore omentin is not a valid 
biomarker of NAFLD.   
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In the NASH group, an optimal omentin cutoff level of 1.83 and 
an area under the curve of 0.71 were obtained, with a 
sensitivity of 58.8 % and specificity 76.2%, reaching the level of 
statistical significance. The negative predictive value (NPV) for 
the NASH group was 91.9 % (Figure 13). 
 
 
Figure 13. ROC curve to detect the presence of NASH in MO 
cohort. 
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Although it has been reported that abnormalities in the 
circulating levels of vaspin and omentin and the gene 
expression of both factors are related to BMI and markers of 
insulin sensitivity in metabolic syndrome patients, the findings 
of various authors to date are confusing. The first objective in 
this study was to measure vaspin and omentin circulating 
levels and mRNA expression in subcutaneous and visceral 
adipose tissues in morbidly obese women and to compare 
them to age-matched controls. We also assessed the 
relationship between these two adipokines and biochemical 
markers of metabolic syndrome and other adipocytokines. 
Because few studies have been conducted to determine the 
relationship between vaspin and omentin in the presence of 
NAFLD, the second most important objective of the present 
study was to relate the circulating levels of vaspin and omentin 
to the presence of NAFLD.  
 
The main results of this study are that omentin circulating 
levels are diminished in morbid obesity, mRNA vaspin 
expression is higher in the VAT and SAT of morbidly obese 
patients and mRNA omentin expression is lower in the VAT of 
morbidly obese women and, finally, omentin circulating levels 
are increased in patients with NASH. 
 
Regarding the relationship of vaspin to obesity and metabolic 
syndrome, we demonstrated that serum vaspin levels were not 
increased in morbidly obese women and that they did not 
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correlate with BMI and markers of glucose or lipid metabolism. 
In studies involving humans, results are controversial. A meta-
analysis encompassing six studies including 1826 obese 
individuals and 11 studies including 1570 subjects with T2DM 
provides evidence of higher vaspin levels in obesity and T2DM 
and emphasizes the pivotal role of vaspin in the progression of 
metabolic and glucose abnormalities, thus its promising 
potential as a cardiovascular risk marker 263. Saboori et al 
demonstrated that the serum vaspin level was significantly 
higher in obese women 264. Youn et al reported that elevated 
vaspin serum concentrations correlated with obesity and 
impaired insulin sensitivity, although not in patients with type 2 
diabetes 269. In obese children, Lee et al observed a negative 
correlation between vaspin concentration and HOMA-IR 265. A 
significant difference in vaspin levels has been observed in 
subjects with newly diagnosed T2DM and MetS compared to a 
group without MetS 266. 
However, in agreement with our results, von Loeffelholz et al 
have shown that no association exists between serum vaspin 
and HOMA-IR in nondiabetic humans 267. Seeger et al also 
reported that circulating vaspin was not independently 
associated with markers of glucose metabolism 268, whereas 
Briana et al demonstrated that vaspin concentrations did not 
correlate with insulin levels in maternal, fetal and neonatal 
samples 269, as occurred in our population.  
The exact reasons for the variability in serum vaspin 
concentrations remain debatable. A difference in the 
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measurement ranges between ELISA and RIA human vaspin 
systems have been observed 269,271. Moreover, Breitfeld et al 
conducted a genome-wide association study and identified 
several single nucleotide polymorphisms (SNPs) in the vaspin 
locus of chromosome 14 associated with serum vaspin levels 
and inferred that genetic variations are the most likely reason 
for serum vaspin variations 270. 
 
Regarding the relationship between vaspin levels and other 
adipocytokines in the circulation, in our study, serum vaspin 
levels correlated inversely with levels of LCN-2 and IL-6. LCN-2 
has been reported to be an adipokine that appears to be an 
independent risk factor for hyperglycemia and insulin 
resistance in humans; moreover, it has also been related to 
inflammation 272. IL-6 is a known proinflammatory cytokine that 
is also increased in obesity 273. Taken together, these findings 
might suggest that vaspin has an anti-inflammatory profile.  
 
Alternatively, vaspin mRNA expression was significantly higher 
in our morbidly obese cohort in the SAT and VAT. Kloting et al 
have reported that vaspin expression was not detectable in 
lean subjects but that it was present in both the SAT and VAT 
of obese patients. Its levels were significantly correlated with 
parameters of obesity, insulin resistance and impaired glucose 
tolerance. However, we have been unable to support their 
findings. In untreated OLETF rats, vaspin expression and its 
serum levels decreased as diabetes worsened and body 
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weight fell. The expression and serum levels were normalized 
by treatment with insulin or pioglitazone, suggesting that vaspin 
exerts a defensive action against insulin resistance. In contrast, 
the administration of recombinant human vaspin improved 
insulin sensitivity and glucose tolerance, and reversed the 
expression of those genes that may promote insulin resistance 
such as leptin, resistin and TNF-α in diet-induced obese mice 
274.   
In summary, serum vaspin levels are inversely related in our 
study to IL-6, whereas SAT and VAT vaspin expression is 
significantly higher in morbidly obese women. Additionally, as 
noted above, the literature confirms that vaspin has an insulin-
sensitizing effect. Thus, in conjunction with our results, this 
finding suggests that vaspin has a compensatory role in the 
inflammatory complications of obesity. 
 
Regarding omentin, another important finding of our study is 
that plasma omentin levels are significantly lower in the 
morbidly obese and that these levels inversely correlate with 
glucidic metabolism parameters, in accordance with other 
authors 150, 153, 275, 276. The exact factors contributing to 
markedly reduced circulating omentin levels in obesity and 
diabetes remain to be determined. Considering the results of 
previous studies 150,180, the increased insulin levels typically 
found in patients with obesity and T2DM might be an important 
contributor preceding decreased omentin levels. Another 
possible factor contributing to decreased omentin levels could 
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be excessive adiposity and obesity-associated metabolic 
complications. This possibility is supported by the finding of 
increased circulating levels of omentin in patients with anorexia 
nervosa with severely reduced body fat content 277. and the 
finding that serum omentin levels were significantly increased 
after bariatric surgery, whereas its mRNA expression in SAT 
was significantly reduced after the surgery, described by 
Urbanova et al and Lapointe et al 276,278. 
In the same context, we found a negative correlation with 
systolic blood pressure. Urbanova et al have also reported that 
serum omentin concentrations negatively correlated with 
parameters of metabolic syndrome 276. We also demonstrate 
that patients with omentin levels in the lowest tertile were 90 
times more likely to have the MetS than those in the highest 
tertile, after adjustment for age and BMI. Moreover, women 
with omentin levels in the second tertile were 25 times more 
likely to have MetS.  
 
Omentin expression in visceral adipose tissue was significantly 
lower in the morbidly obese women in our study, in agreement 
with the results of Souza et al 150. Moreover, Cai et al 
demonstrated that omentin mRNA expression decreased in 
overweight/obese individuals and decreased further when 
overweight/obesity was combined with type 2 diabetes. Thus, 
omentin expression is negatively correlated wiGENCth fasting 
insulin, HOMA-IR and BMI 160.  
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In the study of Urbanova et al, omentin mRNA expression in 
subcutaneous adipose tissue did not correlate with any of the 
anthropometric and biochemical parameters studied 276. 
However, these authors did not study visceral adipose tissue.  
 
We performed this analysis in light of the few studies to 
analyze circulating levels of vaspin and omentin in patients with 
NAFLD and the suggestion that circulating levels of these 
molecules might serve as useful biomarkers in the histologic 
diagnostic of NAFLD 289, 290. Regarding vaspin levels, we did 
not observe differences between the groups. Vaspin was 
associated with liver histology in two studies with biopsy-
proven NAFLD patients. Kukla et al found a positive 
relationship between circulating levels of vaspin and 
hepatocyte ballooning in an obese NAFLD cohort 291. Aktas et 
al indicated that vaspin positively correlated with liver fibrosis, 
independent of confounding factors such as sex, age and 
metabolic and histological parameters 292. The latter study 
group found significantly elevated circulating vaspin levels in 
NAFLD patients compared with healthy controls, whereas 
Kukla et al only found significantly higher adipokine levels in 
NAFLD patients with hepatocyte ballooning. Circulating vaspin 
levels were not found to be associated with the histologic 
findings in a recent study with non-diabetic, non-obese NASH 
patients by Genc et al 282. Although they also reported 
significantly higher levels in NASH patients versus normal liver 
controls, the significance was unapparent after adjustment for 
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the metabolic risk factors. Therefore, the role of vaspin in 
NAFLD at this time is unclear 279. 
 
The results obtained suggest that circulating omentin levels 
tended to be higher in MO women with NAFLD compared to 
MO women with normal liver histology. Subsequently, we 
aimed to analyze whether differences existed between 
circulating omentin levels of patients with SS and NASH. 
Surprisingly, we found that circulating omentin levels were 
increased in patients with NASH. In this regard, Yilmaz et al 
found similar but not identical results. They suggested that 
serum omentin levels are raised in patients with NAFLD 
regardless of potential confounders and represent an 
independent predictor of hepatocyte ballooning 281. As 
previously mentioned, serum omentin is generally considered 
to be negatively associated with insulin resistance and obesity 
280,150. Although these observations might suggest that omentin 
levels should be lower in NAFLD, not higher, the present 
knowledge of the mechanisms by which omentin might be 
regulated in nonalcoholic fatty liver disease does not allow us 
to derive conclusions regarding this topic. A salient finding of 
the present analysis was the increase in serum omentin levels 
in our NASH patients. No information is available concerning 
this finding, and additional studies are required to identify 
reasons for this paradoxical increase. In particular, future 
studies must delineate whether levels of omentin are higher in 
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the NASH population because of a compensatory counter-
regulatory mechanism.  
 
The performance of omentin for the diagnosis of NASH showed 
an excellent area under the receiver operating characteristics 
(ROC) curve. The main adipokines and cytokines involved in 
the pathogenesis of NAFLD include adiponectin, leptin, resistin, 
visfatin, TNF-α and interleukin-6 293. Adiponectin modifies 
insulin receptor function and influences hepatocellular free fatty 
acid metabolism 283. Adiponectin levels were low in NAFLD 
patients 284. Hypoadiponectinemia in NAFLD is part of the 
metabolic disturbances associated with MetS, with a significant 
inverse relationship found between serum adiponectin levels 
and hepatic fat content 285. Another prominent adipocytokine 
associated with NAFLD is leptin. Increases in leptin levels and 
decreases in adiponectin levels occurred similarly in patients 
with simple steatosis or NASH during obesity reversal after 
bariatric surgery, suggesting that these changes are due to 
morbid obesity and occur independently of liver disease 286. In 
a separate study, leptin and adiponectin levels remained 
independent predictors for NASH in obese patients 287. Serum 
levels of retinol-binding protein-4, another adipokine associated 
with insulin resistance, were also higher in NAFLD patients 
compared with controls 288. 
In sum, omentin could represent a good biomarker of NASH, 
probably in conjunction with other adipokines. Further studies 
should be performed to confirm our results.  
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The major limitation of the present study is the relatively small 
number of subjects in the sample. Although our specific cohort 
of morbidly obese women showed a clear relationship between 
the MetS and omentin levels without the interference of 
confounding factors, these results cannot be extrapolated to 
other obesity groups or men. Second, due to the difficulty of 
obtaining tissue samples, the expression results must be 
confirmed in larger study populations.  Another limitation of the 
study is that it is cross-sectional. We could not prove a causal 
link between the levels of omentin and the development of 
MetS or the levels of vaspin and anti-inflammatory action. 
Similarly, our cohort of severely obese women made it possible 
to establish clear relationships between NASH and circulating 
omentin levels without the interference of such confounding 
factors as gender or age. Further prospective studies are 
required to explain these phenomena. 
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The conclusions of this study are as 
follows: 
 
1. No differences were found between circulating levels of 
vaspin in morbidly obese women compared to the 
normal-weight control group. Serum vaspin levels were 
not related to the metabolic variables studied or to 
metabolic syndrome parameters. A significant inverse 
relationship was found with lipocalin-2, leptin and 
IL-6 levels. 
 
2. The circulating levels of omentin were decreased 
significantly in the group of morbidly obese women 
compared to the normal-weight control group. These 
levels showed an inverse correlation with glucose and 
HOMA2-IR levels; similarly, low circulating levels of 
omentin were significantly associated with the 
presence of metabolic syndrome diagnostic criteria. 
A significant relationship with other adipokines could not 
be established. 
 
3. Vaspin gene expression in both subcutaneous and 
visceral adipose tissues was significantly increased 
in the MO group compared to the control group. 
However, no differences could be found between vaspin 
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gene expression in visceral and subcutaneous adipose 
tissues.  
 
4. Vaspin gene expression in both types of visceral and 
subcutaneous adipose tissues was not correlated with 
obesity, glucose metabolism or the metabolic syndrome 
parameters studied. 
 
5. Omentin gene expression in subcutaneous adipose 
tissue was similar in the morbidly obese group and the 
control group. However, omentin gene expression in 
visceral adipose tissue was shown to be 
significantly lower in morbidly obese individuals 
when compared to normal-weight controls. Omentin 
gene expression was observed to be higher in 
visceral adipose tissue with respect to gene 
expression in subcutaneous tissue in both groups. 
 
6. Omentin gene expression in both visceral and 
subcutaneous adipose tissues did not correlate with 
obesity, glucose metabolism or insulin resistance 
parameters. No relationship could be established 
between omentin gene expression and lipid metabolism, 
blood pressure or other adipokines. 
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7. Circulating levels of omentin tended to be higher in 
the subgroup of MO women who demonstrated liver 
histology indicative of NAFLD compared to MO 
women having normal liver histology. 
 
8. Omentin levels were significantly increased in the 
group of MO individuals with nonalcoholic 
steatohepatitis compared to those MO individuals with 
liver steatosis. 
 
9. The performance of omentin for the diagnosis of 
NASH showed an excellent area under the receiver 
operating characteristics curve, suggesting its 
potential utility as a biomarker. 
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New adipokines vaspin and omentin. Circulating
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Abstract
Background: Vaspin and omentin are recently described molecules that belong to the adipokine family and seem
to be related to metabolic risk factors. The objectives of this study were twofold: to evaluate vaspin and omentin
circulating levels and mRNA expression in subcutaneous and visceral adipose tissues in non-diabetic morbidly
obese women; and to assess the relationship of vaspin and omentin with anthropometric and metabolic
parameters, and other adipo/cytokines.
Design: We analysed vaspin and omentin circulating levels in 71 women of European descent (40 morbidly obese
[BMI ≥ 40 kg/m2] and 31 lean [BMI ≤ 25]). We assessed vaspin and omentin gene expression in paired samples of
visceral and subcutaneous abdominal adipose tissue from 46 women: 40 morbidly obese and 6 lean. We
determined serum vaspin and plasma omentin levels with an Enzyme-Linked Immunosorbent Assay and adipose
tissue mRNA expression by real time RT-PCR.
Results: Serum vaspin levels in the morbidly obese were not significantly different from those in controls. They
correlated inversely with levels of lipocalin 2 and interleukin 6. Vaspin mRNA expression was significantly higher in
the morbidly obese, in both subcutaneous and visceral adipose tissue.
Plasma omentin levels were significantly lower in the morbidly obese and they correlated inversely with glucidic
metabolism parameters. Omentin circulating levels, then, correlated inversely with the metabolic syndrome (MS).
Omentin expression in visceral adipose tissue was significantly lower in morbidly obese women than in controls.
Conclusions: The present study indicates that vaspin may have a compensatory role in the underlying
inflammation of obesity. Decreased omentin circulating levels have a close association with MS in morbidly obese
women.
Keywords: circulating levels morbid obesity, mRNA tissue expression, omentin, vaspin
Background
The incidence of obesity is rising rapidly in industria-
lized and developing countries. Increased abdominal
visceral fat is associated with insulin resistance, type 2
diabetes, and coronary heart disease [1]. Reduction of
visceral fat mass by omentectomy has significant posi-
tive and long-term effects on glucose metabolism,
insulin sensitivity, and metabolic profiles in obese sub-
jects [2]. In the last decade, numerous studies have
revealed that adipose tissue secretes a variety of bioac-
tive substances that could explain the epidemiologic
relationship between visceral fat mass and increased
metabolic risk. These substances, termed adipokines,
include leptin [3], adiponectin [4], resistin [5], lipocalin
2(LCN2) [6], fatty acid binding proteins (AFABP) [7],
plasminogen activator inhibitor-1 [8], interleukin 6 (IL
6) [9], and various growth factors. They are considered
to play an important role in interactions between a
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variety of systems, including adrenal, immune, and
central and peripheral nervous systems [10]. In obese
subjects, expression, synthesis and release of pro-
inflammatory cytokines (tumor necrosis factor-alpha
[TNF-a], IL 6) and adipokines (leptin, resistin) is
enhanced but anti-inflammatory adipokines such as
adiponectin are decreased [11].
Recently, vaspin (visceral adipose tissue-derived ser-
ine protease inhibitor) was identified as a member of
the serine protease inhibitor family. Vaspin cDNA
was isolated from visceral white adipose tissues
(WAT) of Otsuka Long-Evans Tokushima Fatty
(OLETF) rats, an animal model of abdominal obesity
with type 2 diabetes [12]. Vaspin is highly expressed
in rat adipocytes from visceral WAT at the age when
obesity and insulin plasma concentrations reach a
peak [13]. Vaspin improves insulin sensitivity in mice
[13]. However, in humans the effect of vaspin on
insulin sensitivity is uncertain and the correlation
between vaspin and body mass index (BMI) is also
unclear [14,15].
Omentin 1 was identified as a novel adipokine predo-
minantly secreted by visceral stromal vascular cells but
not adipocytes [16,17]. Furthermore, in vitro experi-
ments revealed that treatment with recombinant omen-
tin-1 enhances insulin-mediated glucose uptake in
human subcutaneous and omental adipocytes, while
increasing Akt/PKB phosphorylation [17]. In cultured
adipocytes, omentin 1 production is decreased by D-glu-
cose and insulin [18,19].
Nevertheless, in studies involving humans, the plasma
concentration of omentin-1-the major circulating iso-
form in human plasma-is decreased in patients with
type 1 diabetes mellitus [18,19] and not affected by glu-
cose ingestion [20]. In addition, omentin plasma levels
and omentin gene expression in visceral adipose tissue
are decreased in obesity [19].
Although some studies have focused on the abnormal
levels of vaspin and omentin in metabolic syndrome
patients and mRNA expression, particularly with refer-
ence to BMI and markers of insulin sensitivity, the regu-
lation of these molecules and their relationship with
other adipokines in morbidly obese patients has not
been specifically studied.
Our objective in this study was to measure the circu-
lating levels of vaspin and omentin and mRNA expres-
sion in subcutaneous and visceral adipose tissue in
morbidly obese women and make a comparison with
age-matched control women (we studied only women to
avoid sex differences). We also assessed the relationship
between these two adipokines and biochemical markers
of metabolic syndrome, levels of other adipokines, and
pro-inflammatory cytokines.
Methods
Subjects
The study was approved by the institutional review
board. All participants gave written informed consent
for participation in medical research. We analyzed the
circulating levels of vaspin and omentin in 71 Spanish
women of European descent: 31 lean (BMI < 25 Kg/m2)
and 40 morbidly obese (BMI > 40). We also analyzed
vaspin and omentin gene expression in paired samples
of subcutaneous and visceral adipose tissue from 46
patients: 6 lean (BMI < 25 Kg/m2) and 40 morbidly
obese (BM I > 40). Adipose tissue samples were
obtained from morbidly obese women and from control
women who underwent bariatric surgery by laparoscopic
gastric by-pass and elective surgery, respectively. Subcu-
taneous adipose tissue biopsies were taken from the
right hypocondrion region and visceral adipose tissue
biopsies were taken from the greater epiploon region.
For each type of surgery, samples were obtained by the
same specialist. Morbidly obese women and controls
were age matched. The weight of all subjects was stable
for at least three months before surgery. Those patients
who had an acute illness, acute or chronic inflammatory
or infective diseases, or an end-stage malignant disease,
were excluded from. Liver and renal diseases were speci-
fically excluded by biochemical work-up. Control or
morbidly obese patients diagnosed as type 2 diabetes
mellitus or receiving hypolipemiant treatment were also
excluded from the study.
Anthropometric Measurements
BMI was calculated as weight divided by height squared
(kg/m2) (according to the criteria of the World Health
Organization [21]. Waist circumference (WC) was mea-
sured at the height of the iliac crest.
Diagnosis of Metabolic Syndrome
Morbidly obese women were further subclassified
according to the presence or absence of the metabolic
syndrome (MS). The MS and metabolic risks are defined
according to the US National Cholesterol Education
Program Adult Treatment Panel III guidelines and mod-
ified as recommended in the latest American Heart
Association/National Heart, Lung, and Blood Institute
Scientific Statement [22] by adopting a lower cutoff for
fasting glucose (5.6 mmol/L). The MS was defined as
having 3 of the following metabolic risk factors: (1) cen-
tral obesity (waist circumference 88 cm in women), (2)
hypertriglyceridemia (fasting triglycerides 1.69 mmol/L
(150 mg/dL)), (3) low HDL cholesterol (fasting HDL
<1.29 mmol/L (50 mg/dl) in women), (4) glucose intol-
erance (fasting glucose 5.6 mmol/L (100 mg/dL)), and
(5) hypertension (sitting blood pressure 130/85 mm Hg
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obtained as a mean of two readings taken after resting
for at least 10 minutes or on regular antihypertensive
medications).
Analytical Methods
Basal, fasting blood samples were taken after an over-
night fast to determine glucose, insulin, and standard
laboratory parameters. Plasma and serum samples were
stored at -80°C until analytical measurements were per-
formed, except for glucose, which was determined
immediately after blood was drawn.
Fasting plasma glucose and lipid profile (triglycerides,
total cholesterol, and high-density lipoprotein choles-
terol) were measured using the usual enzymatic meth-
ods in an ADVIA Centaur auto analyzer. Low-density
lipoprotein cholesterol was calculated as the difference
between total cholesterol, HDL, and triglyceride con-
tent/5 if it was <400 mg/dL. Plasma insulin concentra-
tion was measured by commercial chemiluminescence
assay for ADVIA Centaur (Siemens Medical Solutions S.
L., Barcelona, Spain) according to the manufacturer’s
instructions. The homeostasis model assessment of insu-
lin resistance (HOMA2-IR) was completed using the
HOMA Calculator version 2.2.2 (http://www.dtu.ox.ac.
uk accessed May 2010). Glycosylated hemoglobin
(HbA1c) was measured by a chromatographic method
(Glico Hb Quick Column Procedure, Helena Labora-
tories, Beaumont, TX).
Circulating levels of TNF-RI, TNF-RII (Biosource
Europe S.A., Nivelles, Belgium), IL 6 (Quantikine, R&D
Systems, Minneapolis, USA), adiponectin, HMW adi-
ponectin (Linco Research, Inc., St. Charles, USA),
resistin (Biovendor, Modrice, Czech Republic), leptin
(Biovendor, Modrice, Czech Republic), RBP4, lipocalin
2 (Biovendor, Modrice, Czech Republic), serum vaspin
(Adipogen, Seoul, South Korea) and plasma omentin
(Apotech, Axxora, Nottingham, UK) were measured in
duplicate using enzyme-linked immunosorbent assays
(ELISA) following the manufacturer’s instructions.
TNF-RI assay sensitivity was 50 pg/mL and the inter-
assay and intra-assay coefficients of variation were less
than 5.7 and 1.7%, respectively. TNF-RII assay sensitiv-
ity was 0.1 ng/mL and inter-assay and intra-assay coef-
ficients of variation were less than 3.2 and 3.3%,
respectively. IL 6 assay sensitivity was 0.039 pg/mL
and inter-assay and intra-assay coefficients of variation
were less than 9.6 and 6.9%, respectively. Adiponectin
assay sensitivity was 0.78 ng/mL and inter-assay and
intra-assay coefficients of variation were less than 8.4
and 7.4%, respectively. HMW adiponectin assay sensi-
tivity was 0.5 ng/mL and inter-assay and intra-assay
coefficients of variation were less than 3.8 and 2.6%,
respectively. Resistin assay sensitivity was 33 pg/mL
and inter-assay and intra-assay coefficients of variation
were less than 6.9 and 3.4%, respectively. Leptin assay
sensitivity was 0.2 ng/mL and inter-assay and intra-
assay coefficients of variation were less than 7.6 and
4.4%, respectively. RBP4 assay sensitivity was 0.02 g/L
and inter-assay and intra-assay coefficients of variation
were less than 1.1 and 2.2%, respectively. LCN 2 assay
sensitivity was 0.01 ng/mL and inter-assay and intra-
assay coefficients of variation were less than 5.6 and
4.4%, respectively. Vaspin assay sensitivity was 12 pg/
mL and inter-assay and intra-assay coefficients of var-
iation were <6% and <4%. Omentin assay sensitivity
was 0.4 ng/mL and inter-assay and intra-assay coeffi-
cients of variation were less than 6 and 2.7%,
respectively.
Analysis of Human Vaspin and Omentin Gene Expression
Total RNA was isolated from adipose tissues with the
RNeasy mini kit (Qiagen) according to the manufac-
turer’s protocol and digested with DNase I (RNase-Free
DNase set, Qiagen). RNA quality was evaluated by mea-
suring the 260/280 nm absorbance ratio (≥1.8) and by
electrophoresis. First-strand cDNA was synthesized
using an equal amount of total RNA with the High
Capacity RNA-to-cDNA Kit (Applied Biosystems). Real-
time quantitative PCR was performed in a final volume
of 20 μL, which contained 10 ng of reverse-transcribed
cDNA, 10 μL of 2X Taq Man Fast Universal PCR Mas-
ter Mix (Applied Biosystems) and 1 μL Taq Man Assay
predesigned by Applied Biosystems® for the detection of
vaspin, omentin, and GAPDH, used as a housekeeping
gene. All reactions were performed in triplicate and
were carried out in 96-well plates by using the 7900HT
Fast Real-Time PCR systems (Applied Biosystems).
Statistical Analysis
All the values reported are expressed as mean ± SEM
(standard error of the mean) and were analyzed using
the statistical package SPSS/PC+ for Windows (v.15.0
Chicago, Illinois, USA). Differences between groups
were calculated using either Student’s t test or the One-
way ANOVA analysis. The strength of association
between variables was calculated using Pearson’s
method for parametric variables and the Spearman Rho
correlation test for non-parametric contrasts. Multiple
linear regression analysis with backward variable selec-
tion was performed to identify independent predictors
of HOMA2-IR. The validity of the regression model and
its assumptions was assessed with the plot of residuals
vs. predicted values. Data were normally distributed.
Logistic regression analysis was performed to identify
independent predictors of the metabolic syndrome. Vas-
pin and omentin circulating levels were age and BMI
adjusted in some analyses. P values < 0.05 were consid-
ered to be statistically significant.
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Results
Population studied
The baseline patient characteristics given in Table 1
show the mean and SEM of the variables of interest.
Patients were separated into control subjects (BMI < 25
kg/m2), and morbid subjects (BMI > 40 kg/m2). The
two groups were well matched for age.
Biochemical analyses indicated that obese women had
significantly higher levels of glucose, insulin, HOMA2-
IR and HbA1c than the control group. Blood pressure
was also increased in the morbidly obese women. The
lipidemic profile differed significantly between groups.
Obese patients showed higher triglyceride levels and
lower HDL cholesterol.
Serum vaspin
Mean ± SD serum vaspin was 0.87 ± 0.96 μg/liter in the
morbidly obese women and not significantly different
from the values of the control group (1.66 ± 2.09 μg/
liter) (Figure 1).
Serum vaspin concentrations did not correlate with
metabolic variables (Table 2) and inversely correlated
with levels of LCN2, leptin and IL 6 (Table 3).
We investigated the relationship between vaspin circu-
lating levels and the presence of the MS but we found
no correlation (Table 4). As expected, the MS correlated
with the BMI, WC, HOMA2-IR, fasting glucose, blood
pressure, HDL cholesterol and triglycerides.
Subcutaneous and visceral vaspin mRNA expression
Vaspin mRNA expression was significantly higher in
morbidly obese women than in controls, in both SAT
and VAT (Figure 2). We found no differences between
visceral and subcutaneous vaspin expression in the adi-
pose tissues of the obese group (p = 0.192) and the con-
trol group (p = 0.934) (Figure 2).
SAT and VAT vaspin mRNA expression did not cor-
relate with obesity, glucose metabolism, insulin resis-
tance parameters, blood pressure, other adipokines
studied or inflammatory parameters (data not shown).
Plasma omentin-1
Mean ± SD plasma omentin was 1.97 ± 2.15 ng/mL in
the morbidly obese group and significantly different from
that of the control group (5.27 ± 5.33 ng/mL) (Figure 1).
Plasma omentin levels inversely correlated with fasting
glucose and HOMA2-IR (Table 2) and did not correlate
with the adipokines or cytokines studied (Table 3).
When we investigated the relationship between omentin
circulating levels and the presence of the MS, we found
that omentin correlated negatively with the MS
(Table 4). After adjustment for age and BMI, we sub-
classified the subjects in three tertiles in accordance
with their omentin levels: tertile 1 (>4.33 ng/ml); tertile
2 (4.33-2.30 ng/ml); tertile 3 (<2.30 ng/ml). In a logistic
regression analysis, the lowest omentin levels (tertile 2
and 3) were associated with the presence of MS while
the highest tertile (tertile 1) was not (Table 5).
Visceral and subcutaneous omentin expression
Omentin mRNA expression in SAT was similar in mor-
bidly obese women and controls. However, omentin
expression in VAT was significantly lower in morbidly
obese women than in controls (Figure 2). When com-
paring both adipose tissues, we found that omentin
expression was higher in VAT than in SAT in both the
obese group (p = 0.009) and the control group (p =
0.034) (Figure 2).
SAT and VAT omentin mRNA expression did not
correlate with obesity, glucose metabolism or insulin
resistance parameters. Neither was there any correlation
with lipid metabolism, blood pressure or the other adi-
pokines and cytokines studied (data not shown).
Discussion
It has been reported that abnormalities in the circulating
levels of vaspin and omentin and the gene expression of
both factors are related to BMI and markers of insulin
sensitivity in metabolic syndrome patients, although to
date, the findings of various authors are confusing. Our
objective in this study was to measure vaspin and omen-
tin circulating levels and mRNA expression in subcuta-
neous and visceral adipose tissue in morbidly obese
women and to compare them to age-matched controls.
We also assessed the relationship between these two
adipokines and biochemical markers of metabolic syn-
drome and other adipo/cytokines.
Table 1 Baseline characteristics, anthropometric
measurements, and metabolic analysis of the population
studied
CONTROL
(n = 31)
MORBID OBESE
(n = 40)
p-value
BMI (Kg/m2) 23.21 ± 0.46 48.22 ± 1.07 <0.001
WC (cm) 80.40 ± 2.16 134.00 ± 3.10 <0.001
AGE (years) 43.53 ± 3.08 46.37 ± 1.54 0.414
GLUCOSE (mg/dL) 94.06 ± 2.53 117.70 ± 4.25 0.001
INSULIN (mU/L) 8.25 ± 1.32 22.69 ± 3.94 0.001
HOMA2-IR 1.11 ± 0.18 2.60 ± 0.24 <0.001
HbA1c (%) 4.55 ± 0.07 5.63 ± 0.29 0.001
HDL-C (mg/dL) 59.83 ± 2.87 40.97 ± 1.33 <0.001
TRIGLYCERIDES (mg/dL) 95.13 ± 9.06 183.52 ± 11.88 <0.001
SBP (mm Hg) 120.91 ± 4.22 134.99 ± 4.07 0.020
DBP (mm Hg) 70.04 ± 1.96 76.70 ± 2.80 0.056
BMI: body mass index, WC: waist circumference, HOMA2-IR: homeostatic
model assessment method insulin resistance, HDL-C: high density lipoprotein
cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure. Data
are the mean ± SEM. * indicates significant differences vs. control group
(p < 0.05).
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In the current study, we demonstrate that serum vas-
pin levels are not increased in morbidly obese women
and that vaspin levels do not correlate with BMI, mar-
kers of glucose or lipid metabolism.
In studies involving humans, and as has been men-
tioned in the introduction, how vaspin serum levels cor-
relate with BMI, markers of insulin sensitivity and
glucose metabolism is unclear. Youn et al. have reported
that elevated vaspin serum concentrations correlated
with obesity and impaired insulin sensitivity, although
not in patients with type 2 diabetes [14]. In obese chil-
dren, Lee et al. have observed a negative correlation
between vaspin concentration and HOMA-IR [23].
However, in agreement with our results, von Loeffelholz
et al. have shown that there is no association between
serum vaspin and HOMA-IR in nondiabetic humans
[24]. Seeger et al. have also reported that circulating vas-
pin is not independently associated with markers of glu-
cose metabolism [15], and Briana et al. have shown that
vaspin concentrations do not correlate with insulin
levels in maternal, fetal and neonatal samples [25], as
occurs in our population.
To our knowledge, this is the first time that the rela-
tion between vaspin levels and other adipo/cytokines in
the circulation has been studied.
In our study, serum vaspin levels correlate inversely
with levels of LCN2 and IL 6. It has been reported that
LCN2 is an adipokine that seems to be an independent
risk factor for hyperglycemia and insulin resistance in
humans. It has also been related to inflammation [26].
IL 6 is a known proinflammatory cytokine that also
increased in obesity [9]. Taken together, these findings
might suggest that vaspin has an anti-inflammatory
profile.
On the other hand, vaspin mRNA expression is signif-
icantly higher in our morbidly obese cohort in SAT and
VAT. Kloting et al. have reported that vaspin expression
was not detectable in lean subjects but that it was pre-
sent in both the SAT and VAT of obese patients. Its
levels were significantly correlated with parameters of
obesity, insulin resistance and impaired glucose
Figure 1 Vaspin and omentin concentrations in control women and morbidly obese women. * Indicates statistically significant differences
between groups (p < 0.05).
Table 2 Correlation of vaspin and omentin levels with
metabolic variables
Circulating levels VASPIN OMENTIN
Variables r p-value r p-value
BMI (kg/m2) -0.181 0.134 -0.212 0.096
WC (cm) -0.448 0.007 -0.332 0.078
Glucose (mg/dL) -0.002 0.989 -0.276 0.029
Insulin (mU/L) -0.015 0.903 -0.252 0.054
HOMA2-IR 0.004 0.976 -0.274 0.037
HbA1c (%) -0.181 0.218 0.011 0.943
HDL-C (mg/dL) 0.166 0.183 -0.178 0.182
Triglycerides (mg/dL) -0.218 0.072 -0.101 0.433
SBP (mm Hg) -0.002 0.986 -0.179 0.201
DBP (mm Hg) -0.019 0.887 -0.072 0.608
BMI: body mass index, WC: waist circumference, HOMA2-IR, homeostatic
model assessment method insulin resistance; HDL-C: high density lipoprotein
cholesterol, SBP: systolic blood pressure, DBP: diastolic blood pressure. Bolded
p-values indicate statistically significant correlations (p < 0.05).
Table 3 Correlation of vaspin and omentin levels with
circulating adipo/cytokine levels
Circulating levels VASPIN OMENTIN
Variables r p-value r p-value
HMW adiponectin (μg/L) 0.178 0.173 0.078 0.557
Adiponectin (μg/L) 0.145 0.250 0.103 0.431
Resistin (μg/L) -0.178 0.157 -0.150 0.236
LCN2 (μg/L) -0.336 0.016 0.088 0.559
IL6 (ng/L) -0.290 0.029 0.033 0.812
RBP4 (mg/dL) 0.015 0.915 0.013 0.931
TNFRI (μg/L) -0.241 0.057 0.004 0.976
TNFRII (μg/L) -0.051 0.689 0.036 0.787
Leptin (μg/L) -0.290 0.041 0.195 0.199
HMW adiponectin: high molecular weight adiponectin, LCN2: lipocalin 2, IL6:
interleukin 6, RBP4: retinol binding protein 4, TNFRI: tumor necrosis factor
receptor I, TNFRII: tumor necrosis factor receptor II. Bolded p-values indicate
statistically significant correlations (p < 0.05).
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tolerance [27]. However, we have not been able to sup-
port their findings.
In untreated OLETF rats, vaspin expression and its
serum levels decreased as diabetes worsened and body
weight fell. The expression and serum levels were normal-
ized by treatment with insulin or pioglitazone, suggesting
that vaspin exerts a defensive action against insulin resis-
tance. On the other hand, the administration of recombi-
nant human vaspin improved insulin sensitivity and
glucose tolerance, and reverses the expression of those
genes that can promote insulin resistance such as leptin,
resistin and TNF-a, in diet-induced obese mice [13].
To sum up, in our study serum vaspin levels are
inversely related to IL 6. SAT and VAT vaspin expres-
sion is significantly higher in morbidly obese women.
In addition, as mentioned above, the literature confirms
that vaspin has an insulin-sensitizing effect. In conjunc-
tion with our results, then, this suggests that vaspin has
a compensatory role in the inflammatory complications
of obesity.
The second important finding of our study is that
plasma omentin levels are significantly lower in the
morbidly obese and that these levels inversely correlate
with glucidic metabolism parameters, in accordance
with the findings of de Souza et al. [19] and Yang et al.
[17]. In the same context, we found a negative correla-
tion with systolic blood pressure.
We also demonstrate that patients with omentin levels
in the lowest tertile were 90 times more likely to have
the MS than those in the highest tertile, after adjust-
ment for age and BMI. Moreover, women with omentin
levels in the second tertile were 25 times more likely to
have the MS.
Omentin expression in visceral adipose tissue is sig-
nificantly lower in the morbidly obese women in our
study in agreement with the results of Souza et al [19].
Also, Cai et al. demonstrate that omentin mRNA
expression decreases in overweight/obese individuals
and decreases further when overweight/obesity is com-
bined with type 2 diabetes. Thus, omentin expression
is negatively correlated with fasting insulin, HOMA-IR
and BMI [28].
The major limitation of the present study is the rela-
tively small number of subjects in the sample. Although
our specific cohort of non-diabetic morbidly obese
women showed a clear relationship between the MS
and omentin levels without the interference of con-
founding factors, these results are not extrapolable to
other obesity groups or men. Secondly, due to the diffi-
culty of obtaining tissue samples, the expression results
Table 4 Correlations between the number of diagnostic
criteria of metabolic syndrome met by the patients
Number of criteria of Metabolic syndrome
Variables r p-value
VASPIN (μg/L) -0.209 0.083
OMENTIN (μg/L) -0.264 0.045
BMI (kg/m2) 0.737 <0.0001
WC (cm) 0.783 <0.0001
HOMA2-IR 0.589 <0.0001
Glucose (mg/dL) 0.710 <0.0001
SBP (mm Hg) 0.636 <0.0001
DBP (mm Hg) 0.250 0.006
HDL-C (mg/dL) -0.750 <0.0001
Triglycerides (mg/dL) 0.704 <0.0001
Vaspin and omentin circulating levels and different parameters.
BMI: body mass index, WC: waist circumference, HOMA2-IR: homeostatic
model assessment method insulin resistance, SBP: systolic blood pressure,
DBP: diastolic blood pressure.
Bolded p-values indicate statistically significant Spearman’s correlations (p <
0.05).
Figure 2 mRNA vaspin and omentin expression in control group (C) (n = 6) and morbidly obese women (MO) (n = 40). * indicates
statistically significant differences between control and morbidly obese subjects (p < 0.05).
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need to be confirmed in larger study populations.
Another limitation of the study is that it is cross-sec-
tional. We could not prove a causal link between the
levels of omentin and the development of MS or the
levels of vaspin and anti-inflammatory action. Further
prospective studies are required to explain these
phenomena.
Conclusion
To sum up, our data suggest that vaspin is likely to have
anti-inflammatory/protective action in morbid obesity.
Also, decreased omentin levels have a close association
with MS in women with morbid obesity. Future studies
should also include parameters for weight loss and exer-
cise to observe their effect on vaspin and omentin levels.
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